Stockwinners Market Radar for June 13, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:10 EDT Carvana exec buys $738K in common stock - In a regulatory filing, Carvana disclosed that its Chief Brand Officer Ryan Keeton bought 32K shares of common stock on June 9th in a total transaction size of $738K.

20:05 EDT Cathie Wood's ARK Investment bought 2.8K shares of Tesla today

19:17 EDT Nerdy CEO buys $480K in common stock - In a regulatory filing, Nerdy disclosed that its CEO Charles Cohn bought 150K shares of common stock on June 9th in a total transaction size of $480K.

18:36 EDT Capcom says 'Monster Hunter Rise: Sunbreak' out June 30, 2022 - During Capcom's (CCOEY) Summer Game Fest showcase, the company made a number of key announcements for its upcoming slate of games. The game maker started the showcase by announcing that "Monster Hunter Rise: Sunbreak," a downloadable expansion to 2021's "Monster Hunter Rise," will release June 30, 2022 for Nintendo Switch (NTDOY) and PC via Steam. Capcom went on to provide more gameplay details on upcoming 2023 titles "Street Fighter VI," "Exoprimal," and the remake of "Resident Evil 4." The company also noted that 2021's "Resident Evil Village," which it said has sold over 6M units, will receive a new downloadable expansion called "Winters' Expansion," out October 28, 2022. Capcom added that Resident Evil 7," "Resident Evil 2," and "Resident Evil 3" will receive current-generation upgrades for PlayStation 5 (SONY) and Xbox Series X/S (MSFT) today.

18:02 EDT Atento names Sergio Ribeiro Passos as new CFO - Atento has announced three new appointments to strengthen Atento's position in the industry and to continue supporting its growth strategy in key markets. In order to optimize efficiency in Atento's management, the organization will switch from having five regions to three: North America, South America and EMEA. In this regard, Atento has appointed Sergio Ribeiro Passos as the new CFO of Atento, Dimitrius Oliveira as the new President of the South Region and Cathrine Jooste as Regional Director of the North Region. Passos, who replaces Jose Antonio de Sousa Azevedo who left the company on June 9, will also form part of the company's Executive Committee. Before joining the company, Passos holds over 24 years of experience as a CFO at different companies within the customer experience sector, including Teleperformance, G4S and Tecnologia Bancaria SA.

17:45 EDT DoorDash launches new app features to 'rate, review and discover' - In a blog posting, DoorDash said the company is launching newer ways to "rate, review and discover," the best restaurants in every community. DoorDash will celebrate " most loved restaurants with written reviews, top 10 lists, and most loved all stars, according to the company's blog posting. "We're always thinking about how we can make the shopping experience even more frictionless and relevant for our customers," said Helena Seo, Head of Design at DoorDash. "With the launch of the Most Liked Items feature, we're saving consumers over 400,000 hours annually, reducing decision fatigue when deciding what to order. We're excited for consumers to find the delight in discovering new restaurants and dishes, trusted and loved by locals," added the company's statement. Reference Link

17:37 EDT Rockley Photonics set to join Russell 3000 Index - Rockley Photonics announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022, according to a preliminary list of additions posted June 3, 2022. The Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 6, 2022, ranking them by total market capitalization. Inclusion in the U.S. all-cap Russell 3000 Index remains in place for one year. Companies included in this index are automatically included in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. "We are pleased to announce our inclusion in the Russell index. Being included in the index will expand the visibility of Rockley as we gain more recognition as a public company," said Dr. Andrew Rickman, chairman and chief executive officer of Rockley. "The inclusion in the index not only enhances our visibility within the broader market, but it also raises our profile in the wearables market, where we continue to make great strides in commercializing our biosensing platform, which we believe will profoundly change healthcare by providing a holistic view of a person's health."

17:19 EDT National Vision to replace Renewable Energy in S&P 600 at open on 6/16 - Chevron (CVX) acquired Renewable Energy Group (REGI) in a deal that closed on June 13.

17:01 EDT AssetMark Financial to acquire Adhesion Wealth - AssetMark Financial "announced it has reached an agreement with Vestmark to acquire Adhesion Wealth, a leading provider of wealth management technology solutions to RIAs, RIA enterprises and asset managers. Adhesion's platform enables over 2,800 fee-based advisors across 180 RIAs to deliver better investor outcomes while successfully growing their practices by providing outsourced overlay trading services, client engagement technologies and managed account programs."

16:55 EDT CEO of Stryve Foods Christopher Boever purchases $280K in shares - CEO of Stryve Foods Christopher Boever purchased 250,000 shares of company stock at $1.23 per share on June 10, for a total transaction amount of $280,000.

16:46 EDT Applied Blockchain announces expiration of share lock-up - Applied Blockchain announced the expiration of a share lock-up agreement. In connection with the company's initial public offering, on April 12, 2,040,000 shares of previously existing Applied Blockchain preferred stock were converted into 36,441,489 shares of the company's common stock. The converted stock was restricted from sale until June 11, after which the shares became freely tradeable pursuant to an effective Registration Statement on Form S-1.

16:31 EDT Granite awarded $13M contract for Richardson Highway Resurfacing Project - Granite announced that it has received the approximately $13M contract for the Richardson Highway MP 40-51 Resurfacing project. Located between Valdez, Alaska and Glennallen, Alaska, the project was awarded by Alaska Department of Transportation and Public Facilities Northern Region and will be funded by the federal government. The award is anticipated to be included in Granite's second quarter CAP. The main scope of work is the grinding and paving of around 11 miles of the Richardson Highway. Additional improvements include replacement of cross culverts, guardrail, and bridge repairs. The project is expected to start in July 2022 and anticipated to be complete in July 2023.

16:26 EDT Rocky Mountain Chocolate chair to retire, Jeffrey Geygan to succeed - Rocky Mountain Chocolate has announced that its board of directors unanimously elected Jeffrey Geygan as the board's new chair, effective June 9. He succeeds Elisabeth Charles, who will serve on the board until the conclusion of the company's annual meeting of stockholders to be held on August 18. She will retire from the company following the annual meeting. Charles was elected a director in October 2021 and appointed board chair in January. Geygan joined the Board in August 2021, serving as Interim board chair from October 2021 to January 2022. Additionally, Geygan serves as CEO and president of Global Value Investment Corp., an investment research and advisory services firm he founded in 2007.

16:20 EDT Apollo Funds buys Cardenas Markets from investment firm KKR - Apollo (APO) announced that funds managed by its affiliates have agreed to acquire Cardenas Markets, a grocery retailer focused on serving the Hispanic community, from investment funds affiliated with KKR (KKR), a global investment firm. Upon completion of the transaction, Apollo Funds will combine Tony's Fresh Market, a Chicago-based portfolio company, with Cardenas Markets, which operates across California, Nevada and Arizona, to create a leading Hispanic- and ethnic-focused grocer. Both companies will continue to operate under their respective brands and local leadership, while benefitting from greater scale, complementary capabilities and an expanded operating footprint. Andrew Jhawar and Joanna Reiss, Apollo Private Equity Partners, said: "Cardenas has grown significantly over the last several years under Doug's leadership and we are excited to accelerate its growth in combination with Tony's in this next phase. We are excited to once again partner with Doug following our highly successful investment in Sprouts Farmers Market which Doug led as CEO under Apollo funds' ownership. Cardenas

16:15 EDT Gan Limited authorizes extension of share repurchase plan - Gan Limited announced that its Board of Directors has authorized an extension of the previously authorized share repurchase program which permits the company to purchase up to an aggregate of $5M of its ordinary shares on the NASDAQ Capital Market. The program's expiration date has been extended to November 30, 2022. The shares will be repurchased with cash on hand and cash from operations. Any shares repurchased will be returned to treasury for cancellation. The price which the company will pay for any such shares will be the prevailing market price at the time of acquisition, subject to certain limitations imposed by applicable securities laws. The actual timing, manner, and number of shares repurchased under the program will be determined by management at its discretion, together with further discussions with the board, and will depend on several factors, including the market price of GAN's common shares, general market and economic conditions, alternative investment opportunities, and other business considerations in accordance with applicable securities laws and exchange rules. The authorization does not obligate GAN to acquire any particular number of shares and repurchases may be suspended or terminated at any time at GAN's discretion.

16:10 EDT ICF International awarded $30M contract from Defense Health Agency - The U.S. Department of Defense Defense Health Agency recently awarded ICF a $30M recompete contract to provide research and operational support to help execute the agency's critical military mental health research agenda. The contract has a term of 55 months, including a seven-month base and four one-year options.

16:09 EDT Oracle jumps 9% to $69.74 after Q4 results beat estimates

16:09 EDT Soleno Therapeutics presents new DCCR development program data at ENDO 2022 - Soleno Therapeutics presented new clinical data from its ongoing late-stage DCCR development program for the treatment of Prader-Willi syndrome, or PWS, at ENDO 2022, which is being held June 11-14 in Atlanta, Georgia. Patients experienced improvements in body composition, as evidenced by statistically significant changes in lean body mass and the ratio of lean body mass to fat mass, based on DXA scanning. These changes were accompanied by reduced levels of leptin, fasting insulin and an improvement in insulin sensitivity, likely related to a combination of reduced fat mass and improved leptin resistance. A statistically significant increase of adiponectin, a cardioprotective marker, was also observed. Similar effects were observed in obese participants enrolled in these studies.

16:08 EDT Conmed completes acquisition of In2Bones Global - CONMED "announced that it has completed its previously announced acquisition of privately-held In2Bones Global Inc. The transaction is being financed through a combination of the net proceeds of the Company's 2.25% convertible notes, which were issued on June 6, 2022, borrowings under the Company's amended and restated credit facility, and cash on hand. The Company will provide additional guidance regarding the impact of the transaction on 2022 financial results when it reports second quarter financial results in late July."

16:08 EDT Finance of America CEO Patricia Cook to retire - Finance of America Companies announced that Patricia L. Cook has informed the Board of Directors that she will step down from her role as Chief Executive Officer on June 30, 2022 to focus on her health as she attends to an existing medical condition. In February 2022, Ms. Cook announced her plans to retire while remaining with the Company until her replacement was identified. Given that the Chief Executive Officer search remains in progress, the Board of Directors has appointed Company President Graham A. Fleming as interim-Chief Executive Officer effective July 1, 2022. Mr. Fleming will continue to serve as President of the Company during this interim period where he oversees the Company's Forward, Reverse, Commercial and Home Improvement lending segments, as well as Lender Services. Prior to his current role, Mr. Fleming served as Chief Administrative Officer, overseeing Finance, Treasury, Risk, Compliance and Corporate Administration.

16:08 EDT Booking Holdings' Agoda to partner with Affirm on platform checkout - The companies state: "Affirm (AFRM) announced a partnership with global travel platform Agoda, part of Booking Holdings (BKNG). Now, eligible travelers can book their hotel accommodations for upcoming trips across the Agoda platform both on web and via the app and pay over time for bookings over $50. By selecting Affirm as a checkout option on the platform, eligible travelers can split the total cost of purchases into either biweekly or monthly payments for as low as 0% APR. They are shown the total cost of their purchase and will never pay more than the agreed amount upfront. With Affirm, customers will know exactly what they owe with no additional late charges or hidden fees. Agoda integrates Affirm's Adaptive Checkout to offer customers dynamic payment options to suit a variety of budgets and preferences, including four interest-free biweekly payments as well as monthly payment options."

16:02 EDT Pfizer, MorphoSys, Incyte collaborate over Monjuvi/TTI-622 combination - Pfizer (PFE), MorphoSys U.S. (MOR), and Incyte (INCY) announced a clinical trial collaboration and supply agreement to investigate the immunotherapeutic combination of Pfizer's TTI-622, a novel SIRPalpha-Fc fusion protein, and Monjuvi plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation. "TTI-622 blocks the signal-regulatory protein (SIRP)alpha-CD47 axis, which is a key checkpoint expected to become an important backbone immunotherapy across multiple tumors, especially hematological cancers," said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development. "The early results for TTI-622 in late-line advanced lymphoid malignancies reflect the potential for class-leading monotherapy activity, and preclinical evidence with a diverse set of therapeutic agents provide a strong rationale for testing combination therapies. We are pleased to collaborate with MorphoSys and Incyte, generating additional evidence on the potential of TTI-622 to improve outcomes for patients with DLBCL." Under the terms of the agreement, Pfizer will initiate a multicenter, international Phase 1b/2 study of TTI-622 with Monjuvi and lenalidomide for patients with relapsed or refractory DLBCL who are not eligible for ASCT. MorphoSys and Incyte will provide Monjuvi for the study, which will be sponsored and funded by Pfizer and is planned to be conducted in North America, Europe and Asia-Pacific. The collaboration is effective immediately upon the execution of the agreement.

16:01 EDT Silica Holdings trading resumes

15:43 EDT U.S. Silica concludes review of ISP segment, to retain ownership - U.S. Silica Holdings announced that its board of directors has concluded its previously announced review of strategic alternatives for its Industrial & Specialty Products, or "ISP," segment. "Over the course of the review, which began in October 2021, the board considered a range of options with a goal to maximize shareholder value, including the potential sale or separation of the ISP segment. As part of the review, the company, among other actions, contacted and engaged with both strategic industry parties, as well as private equity investors. After extensive evaluation and deliberation, and in consultation with its independent financial and legal advisors, the board unanimously determined that retaining ownership of the ISP segment represents the best path forward for U.S. Silica and its shareholders. In making its determination, the board determined that a transaction would fail to provide superior value to shareholders as compared to the company's standalone strategic and financial outlook, which has improved substantially since the review began. The board also considered and is pursuing a refinancing of the company's debt at more attractive terms than previously available," the company stated. Charles Shaver, Chairman of the board, added, "After an independent and exhaustive review of strategic alternatives, the board believes continuing to operate the ISP segment and pursuing the company's business plan is the best path forward to maximize value for all shareholders. The board is confident in the company's long-term strategy, growth prospects and ability to generate cash, and will continue to be open to additional opportunities to maximize shareholder value."

15:02 EDT Silica Holdings trading halted, news pending

14:50 EDT SpaceX asks FCC to deny ViaSat $4B deal for Inmarsat - In a filing with the Federal Communications Commission, Elon Musk's SpaceX has asked the U.S. regulator to deny ViaSat's proposed $4B deal for Inmarsat Group. "Space Exploration Holdings hereby requests that the Commission deny the above-referenced application due to Viasat's ongoing willful and unlawful operation of a potentially very large number of U.S. earth stations, including earth stations aboard aircraft, without Commission authorization across one gigahertz of spectrum in the Ka-band. This is a blatant violation of the Commission's rules, causing harm to the operations of others. SpaceX filed a complaint citing this unauthorized use of the spectrum nearly a year ago, and filed a related request for an order to show cause nearly two years ago... The public interest is not served by giving a company with such blatant disregard for the Commission's rules control over the Inmarsat satellite system," the filing reads. Reference Link)]

13:59 EDT Belite Bio Inc (ADR) trading resumes

13:38 EDT User reports indicate problems at Amazon, Downdetector says - Reference Link

13:07 EDT D.E. Shaw Research licenses therapeutic for immunological diseases to Eli Lilly - D. E. Shaw Research announced that it has entered into an exclusive global license agreement with Eli Lilly and Company for the clinical development and commercialization of DESRES's program of Kv1.3-targeted therapeutics for the treatment of various immunological and inflammatory diseases. The lead compound, DES-7114, is an orally administered, highly selective small-molecule inhibitor of the ion channel protein Kv1.3. This first-in-class compound recently completed Phase 1 clinical trials in healthy volunteers and has demonstrated efficacy in preclinical models of several chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease and atopic dermatitis. Under the terms of the agreement, Lilly will make an initial payment of $60M to DESRES, with potential development and commercial milestone payments of up to $475M, as well as royalties on worldwide sales.

12:54 EDT General Motors CEO teases image of electric Chevy Blazer ahead of July 18 reveal - Mary Barra, Chair and CEO of GM, tweeted: "Allow me to share a sneak peek at the all-new @Chevrolet Blazer #EV. I can't wait until July 18, when we share the details with the world." Her tweet was accompanied by an image of a preproduction model of the upcoming SUV that is scheduled to be available in Spring 2023. Reference Link

12:34 EDT BioMarin 'pleased' by 52-week analysis of Phase 2 study of Voxzogo - BioMarin Pharmaceutical presented data at The Endocrine Society Annual Meeting, ENDO 2022, and provided data from a Phase 2 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of VOXZOGO for Injection in infants and children aged 0 to less than five years old. In the overall population of all randomized and sentinel subjects, the study showed an improvement in height Z-score as compared to placebo at 52 weeks. Voxzogo, compared to placebo, increased height Z-score by 0.30 SD and annualized growth velocity by 0.92cm/year. This improvement in height Z-score was consistent with improvements previously observed after one year of treatment in children over five years of age. In the randomized population, excluding sentinel subjects, and in the individual age subgroups, a trend toward increased height Z-score was observed. Voxzogo did not significantly impact upper-to-lower body segment ratio, which changed by -0.06 over this 52-week period. BioMarin intends to meet with regulatory health authorities in the second half of 2022 to discuss next steps to expand access to Voxzogo for the treatment of achondroplasia in younger children. "We are pleased by these 52-week analysis results showing positive changes with Voxzogo compared to placebo in height Z-score and AGV. We look forward to discussing next steps regarding our efforts to expand access to Voxzogo treatment for this younger age group. We remain grateful to the children and families participating in the clinical study program," said Hank Fuchs, M.D., President, Worldwide Research and Development at BioMarin.

12:04 EDT Stellantis to launch 'Freedom of Mobility Forum' - Stellantis N.V. announced the "Freedom of Mobility Forum," a yearly open meeting of "problem-solvers committed to fact-based decision making that identifies how to bring clean, safe, and affordable freedom of mobility for society in the face of global warming implications." The "Freedom of Mobility Forum," initially planned for early 2023, will bring together a pool of experts working toward a common purpose, able to move fast, and capture solutions, embracing a 360-degree analysis of the different problems. As part of this announcement, Stellantis confirms it will cease to be a member of the European Automobile Manufacturer's Association by the end of this year.

12:02 EDT Spotify to acquire AI voice platform Sonantic; financial terms not disclosed - Spotify announced its intention to acquire Sonantic, "a dynamic AI voice platform that creates compelling, nuanced, and stunningly realistic voices from text." The company said in a statement: "Listeners come to Spotify for all of the best audio content in the world-and we believe that Sonantic's technology will allow us to create high-quality experiences for our users by building on our existing technical capabilities." It added: "At Spotify, we've identified several potential opportunities for text-to-speech capabilities across our platform, and we believe that over the long term, high-quality voice will be important to growing our share of listening." Financial terms of the deal have not been disclosed. Reference Link

12:00 EDT ProShares Bitcoin Strategy ETF falls -19.2% - ProShares Bitcoin Strategy ETF is down -19.2%, or -$3.44 to $14.51.

12:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 14.8% - Direxion Daily Semiconductor Bear 3X Shares is up 14.8%, or $7.61 to $59.16.

12:00 EDT Daily S&P Biotech Bear 3x Shares rises 17.0% - Daily S&P Biotech Bear 3x Shares is up 17.0%, or $9.84 to $67.84.

11:37 EDT State Street now sees Q2 fee revenue down 6%-7% vs. prior 2%-3% view - Updated guidance includes servicing fees down 4% and management fees down 5% quarter on quarter. Comments taken from the Morgan Stanley US Financials, Payments & CRE Conference.

11:18 EDT Humana launches CenterWell Pharmacy, CenterWell Specialty Pharmacy - Humana announced that Humana Pharmacy and Humana Specialty Pharmacy are now CenterWell Pharmacy and CenterWell Specialty Pharmacy after making a transition to the CenterWell healthcare services brand. All CenterWell Pharmacy services, including prescription home delivery, over-the-counter fulfillment and retail pharmacies in Humana-owned primary care locations, have adopted the brand while Enclara Pharmacia and Humana Pharmacy Solutions, which is Humana's Pharmacy Benefit Manager, will keep their existing branding and will not transition to the CenterWell brand, Humana said.

11:01 EDT Hanover Bancorp Inc trading resumes

10:22 EDT Telus invests $9M in Mekinac, Les Chenaux to roll out PureFibre, 5G networks - TELUS announces a $9M private investment in the Mekinac and Les Chenaux RCMs, rolling out its PureFibre and 5G networks in Batiscan, Herouxville, Saint-Adelphe and Sainte-Genevieve-de-Batiscan in the upcoming year. TELUS is also extending its 5G network coverage with the construction of a new wireless site in Saint-Adelphe, the company said, adding that this investment will "bridge the digital divide by fostering digital innovation in local businesses, promoting the tourism industry, attracting young workers and families and accelerating the development of virtual services in health and education." TELUS plans to invest $70B in Canada by 2026 for its network infrastructure, operations and spectrum, including $11B in the Quebec economy.

10:14 EDT AeroClean Technologies Inc trading resumes

10:09 EDT AeroClean Technologies Inc trading halted, volatility trading pause

10:05 EDT Charles Schwab says prior results included liability, charge for SEC settlement - Charles Schwab announced it has reached a settlement with the U.S. Securities and Exchange Commission to resolve an investigation into historical disclosures related to the Schwab Intelligent Portfolios advisory solution. The settlement with the SEC involves Schwab Wealth Investment Advisory, Inc., Charles Schwab Investment Advisory, Inc. and Charles Schwab & Co., Inc. Under the terms of the settlement, Schwab will pay $186.5M to resolve the matter, which will be deposited into a Fair Fund account for distribution to affected investors. Schwab will also retain an Independent Compliance Consultant to review CS&Co.'s and CSIA's current supervisory, compliance, and other policies and procedures concerning CS&Co.'s and CSIA's SIP-related disclosures, advertising, and marketing communications with clients or potential clients. As previously disclosed in a Form 8-K filing dated July 1, 2021, Schwab's second quarter 2021 financial results included a liability and related non-deductible charge of $200 million in connection with the settlement. The company issued a statement, stating in part: "Schwab has resolved a matter with the SEC regarding certain historic disclosures and advertising related to Schwab Intelligent Portfolios between 2015-2018, and we are pleased to put this behind us. The SEC Order acknowledges that Schwab addressed these matters years ago. In entering the settlement, Schwab neither admits nor denies the allegations in the SEC's Order. We believe resolving the matter in this way is in the best interests of our clients, company, and stockholders as it allows us to remain focused on helping our clients invest for the future. As always, we are committed to earning our clients' trust every day and work diligently to maintain the highest standards for professional conduct throughout our organization... Schwab has been democratizing investing for almost half a century, and SIP is a direct reflection of this focus... Hundreds of thousands of Americans have benefited from SIP's automated, diversified portfolios, which deliver value, sophistication, tailored solutions and 24/7 support."

10:00 EDT Silvergate Capital falls -14.2% - Silvergate Capital is down -14.2%, or -$10.52 to $63.49.

10:00 EDT Daily S&P Biotech Bear 3x Shares rises 11.4% - Daily S&P Biotech Bear 3x Shares is up 11.4%, or $6.59 to $64.59.

10:00 EDT Canadian Imperial Bank of Commerce (CIBC) rises 12.8% - Canadian Imperial Bank of Commerce (CIBC) is up 12.8%, or $6.83 to $60.15.

09:47 EDT ProShares Bitcoin Strategy ETF falls -18.4% - ProShares Bitcoin Strategy ETF is down -18.4%, or -$3.31 to $14.64.

09:47 EDT New Oriental Education rises 10.6% - New Oriental Education is up 10.6%, or $1.72 to $17.93.

09:45 EDT Seneca Foods trading resumes

09:40 EDT Seneca Foods trading halted, volatility trading pause

09:36 EDT Globis Acquisition Corp trading halted, volatility trading pause

09:30 EDT Global Blockchain Acquisition announces upcoming automatic unit separation - Global Blockchain Acquisition announced that, on June 16, 2022, the Company's units will no longer trade, and that the Company's common stock, rights and redeemable warrants, which together comprise the units will commence trading separately. The common stock, rights and warrants will be listed on the Nasdaq Global Market and trade with the ticker symbols "GBBK," "GBBKR," and "GBBKW", respectively. This is a mandatory and automatic separation, and no action is required by the holders of units. Each unit consists of one share of common stock, one right and one redeemable warrant. Each right entitles the holder thereof to receive one-tenth of one share of common stock upon the consummation of an initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share. Purchases of units that are made after market close on June 14, 2022, may not settle prior to the unit separation date and, accordingly, the number of rights and warrants issued to such purchasers may not reflect the rights and warrants underlying such recently purchased units.

09:18 EDT TC Media acquires ERPI from Pearson - Pearson (PSO) and TC Media, part of Transcontinental Inc. (TCLAF) announce the sale of ERPI by Pearson to TC Media. ERPI is a Quebec educational publisher founded in Montreal in 1965 and acquired by Pearson in 1989.

09:12 EDT Dermata announces final patient enrolled in Phase 2 trial of DMT310 - Dermata Therapeutics announced it has completed enrollment of its Phase 2 trial of DMT310 for the once-weekly treatment of moderate-to-severe rosacea. DMT310 is Dermata's lead product candidate, consisting of a once-weekly topical treatment, utilizing both mechanical and chemical mechanisms of action. DMT310 is currently being investigated to treat multiple inflammatory skin conditions, including rosacea, acne, and psoriasis.

09:11 EDT Dermata Therapeutics completes enrollment in DMT310 trial - Dermata Therapeutics announced it has completed enrollment of its Phase 2 trial of DMT310 for the once-weekly treatment of moderate-to-severe rosacea. DMT310 is Dermata's lead product candidate, consisting of a once-weekly topical treatment, utilizing both mechanical and chemical mechanisms of action. DMT310 is currently being investigated to treat multiple inflammatory skin conditions, including rosacea, acne, and psoriasis.

09:09 EDT SEC says Schwab subsidiaries misled robo-adviser clients about fees - The Securities and Exchange Commission announced it has charged three Charles Schwab investment adviser subsidiaries for not disclosing that they were allocating client funds in a manner that their own internal analyses showed would be less profitable for their clients under most market conditions. The subsidiaries agreed to pay $187M to harmed clients to settle the charges. "According to the SEC's order, from March 2015 through November 2018, Schwab's mandated disclosures for its robo-adviser product, Schwab Intelligent Portfolios, stated that the amount of cash in the robo-adviser portfolios was determined through a 'disciplined portfolio construction methodology,' and that the robo-adviser would seek 'optimal return[s].' In reality, Schwab's own data showed that under most market conditions, the cash in the portfolios would cause clients to make less money even while taking on the same amount of risk. Schwab advertised the robo-adviser as having neither advisory nor hidden fees, but didn't tell clients about this cash drag on their investment," the SEC stated. Reference Link

09:08 EDT NextNav announces The Vitals App has joined NextNav partner ecosystem - The Vitals App has joined the NextNav partner ecosystem to ensure application users can be precisely located in multi-story environments. With the Vitals App, individuals, families and caregivers can share their information as well as request assistance from responders in a means they understand, providing critical details which will ensure a calm, humanized response process. "We founded Vitals with a single purpose in mind - providing a voice and independence to the millions of people needing advocacy, transparency and most importantly a safer outcome when they face an emergency situation," said Janee Harteau, President and CEO of Vitals Aware Services. "While we have a serious mental health epidemic in our nation, that does not mean that millions of people are not able to function in society; rather, Vitals is empowering these individuals and families with the tools they need to maintain and, in times, gain independence, a voice, dignity and quite simply, the basic right to be a productive member of society. One critical factor in this is making sure everyone has a tool to reach our nation's first responders on terms they understand, with information all responders need. By powering our Vitals App with NextNav's precision vertical location service, these individuals will have a means for responders to serve them on terms they relate to, as something as simple as taking a wrong turn in a building can make the difference between a good outcome and a tragic one."

09:07 EDT Summit State Bank announces Reynolds joined board of directors - Summit State Bank (SSBI) announces Douglas Reynolds has joined its Board of Directors. Reynolds was elected to the Board of Directors at the bank's annual meeting of shareholders held on May 23, 2022. Currently, Reynolds is an attorney for Reynolds & Brown. He is the President and Chief Executive Officer of Energy Services of America (ESOA), where he has also served as a director since 2008.

09:05 EDT Becton Dickinson announces collaboration with Mayo Clinic Platform - Becton Dickinson announced a collaboration with Mayo Clinic Platform to access de-identified patient data from Mayo Clinic Platform_Discover to perform detailed post-market surveillance on its products to fuel innovation and unlock a faster, more efficient path to market, with the ultimate goal of improving patient care. Using data mining, next generation artificial intelligence and machine learning tools, BD will analyze the real-world data - which provides information outside what is typically gathered in a clinical trial - to generate deeper insight into the patient experience that will help the company accelerate and enhance innovation around both existing products and unmet needs.

09:05 EDT Gannett announces Vincent Cirel as CTO - Gannett announced Vincent Cirel joining as chief technology officer, or CTO, accelerating Gannett's digital evolution as a data and technology subscription-led business. Partnering with the Digital Marketing Solutions and Gannett Media business units, Cirel will drive the company's enterprise-wide technology vision and strategy, including the company's overall cybersecurity program. He will also work closely with internal partners to ensure ongoing compliance with data privacy rules and regulations. Cirel will report to Gannett's CFO Doug Horne. Cirel brings over two decades of experience, most recently as founder and managing director of Pivotal Technologies.

09:03 EDT Brookfield announces results of annual meeting of shareholders - Brookfield announced that all eight nominees proposed for election to the board of directors by holders of Class A Limited Voting Shares and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares were elected at the company's annual meeting of shareholders held on June 10, 2022 in a virtual meeting format. Management received a proxy from the holder of Class B Shares to vote all 85,120 Class B Shares for each of the eight directors nominated for election by this shareholder class, namely Jeffrey M. Blidner, Jack L. Cockwell, Marcel R. Coutu, Bruce Flatt, Brian D. Lawson, Howard S. Marks, Rafael Miranda and Lord O'Donnell.

09:02 EDT Revelation Biosciences announces completion of dosing for Phase 1b CLEAR study - Revelation Biosciences announced that it has completed enrollment and dosing of its Phase 1b CLEAR clinical study to evaluate safety and efficacy of intranasal REVTx-99b for the treatment of allergic rhinitis. "We are excited to complete enrollment in this study and look forward to reporting the results in the third quarter of 2022," said James Rolke, Chief Executive Officer of Revelation. "As always, we are extremely grateful to the participants who enrolled in this study, as they are essential to the development of new treatment options for this very common medical condition that affects millions of patients." The Phase 1b, randomized, double-blind, placebo-controlled, crossover study design was conducted in Australia. The primary endpoint is to evaluate the effects of REVTx-99b versus placebo on safety and tolerability. Key secondary endpoints include allergy symptoms and peak nasal inspiratory flow elicited by nasal allergen challenge. The study enrolled two cohorts: one cohort received study drug prior to nasal allergen challenge and the second cohort received study drug after the nasal allergen challenge.

08:57 EDT Gladstone Land provides business update to shareholders - Gladstone Land announced that, in light of the recent price volatility of its common stock, it is providing the following business updates to its shareholders: "Inflation Hedge: With inflation continuing at the highest rates seen in over four decades, farmland, as an overall asset class, continues to act as a strong hedge against inflation. According to the U.S. Bureau of Labor Statistics, CPI grew at an annual rate of 8.6% through May 2022. However, food prices have continued to outpace the rate of inflation, with the overall food segment increasing by 10.1% over that same period, and the food at home segment growing by 11.9%. In addition, according to the NCREIF Farmland Index, which, as of March 31, 2022, consisted of 1,284 farms worth approximately $14.4 billion across the U.S., the total return on U.S. farmland was 9.7% for the 12 months ended March 31, 2022. Farmland has historically performed well in both inflationary times and the Company's management expects these trends to continue in light of the current inflationary environment. Western Drought: California continues to struggle with a multi-year drought, as snowpack levels, year-to-date precipitation, and reservoir levels are all below historical averages at most locations throughout the state. These drought conditions are driving farms with poor overall water availability, particularly those with only one source of water, to decrease in value, while farms with more secure water resources continue to increase in value. During the quarter ended March 31, 2022, 23 of the Company's farms in California were revalued via third-party appraisals. Overall, these farms increased in value by approximately $13.0 million, or 5.4%, over their prior valuations from about a year ago. Management attributes this to the diligence process followed by our deal team in identifying prime farmland with strong sources of water. Increased Input Costs: Certain input costs, particularly fertilizer and transportation costs, have surged over the past year. However, market situations like the current one, with food prices also rising faster than inflation, help to mitigate the impact of these rising costs. Further, many larger farmers, especially the types of tenants we generally lease to, had already locked in fertilizer and diesel prices at the start of the year. As of today, management is not aware of any significant impact to the Company's tenants, and none of them have reported reducing acreage as a result of rising input costs."

08:56 EDT Prologis falls over 5% after entering all-stock merger with Duke Realty - Shares of Prologis are down 5.3% at $111.02 after the company entered into an all-stock merger with Duke Realty, which is up 2.6% on the announcement.

08:53 EDT Gladstone Land provides business update to shareholders - Gladstone Land announced that, in light of the recent price volatility of its common stock, it is providing the following business updates to its shareholders: Inflation Hedge: With inflation continuing at the highest rates seen in over four decades, farmland, as an overall asset class, continues to act as a strong hedge against inflation. According to the U.S. Bureau of Labor Statistics, CPI grew at an annual rate of 8.6% through May 2022. However, food prices have continued to outpace the rate of inflation, with the overall food segment increasing by 10.1% over that same period, and the food at home segment growing by 11.9%. In addition, according to the NCREIF Farmland Index, which, as of March 31, 2022, consisted of 1,284 farms worth approximately $14.4 billion across the U.S., the total return on U.S. farmland was 9.7% for the 12 months ended March 31, 2022. Farmland has historically performed well in both inflationary times and the Company's management expects these trends to continue in light of the current inflationary environment. Western Drought: California continues to struggle with a multi-year drought, as snowpack levels, year-to-date precipitation, and reservoir levels are all below historical averages at most locations throughout the state. These drought conditions are driving farms with poor overall water availability, particularly those with only one source of water, to decrease in value, while farms with more secure water resources continue to increase in value. During the quarter ended March 31, 2022, 23 of the Company's farms in California were revalued via third-party appraisals. Overall, these farms increased in value by approximately $13.0 million, or 5.4%, over their prior valuations from about a year ago. Management attributes this to the diligence process followed by our deal team in identifying prime farmland with strong sources of water. Increased Input Costs: Certain input costs, particularly fertilizer and transportation costs, have surged over the past year. However, market situations like the current one, with food prices also rising faster than inflation, help to mitigate the impact of these rising costs. Further, many larger farmers, especially the types of tenants we generally lease to, had already locked in fertilizer and diesel prices at the start of the year. As of today, management is not aware of any significant impact to the Company's tenants, and none of them have reported reducing acreage as a result of rising input costs. Almond Exports: According to the Almond Board of California, California produces approximately 80% of the world's conventional almonds, with approximately 65% of the crop exported to more than 90 countries worldwide. Recently, shipping issues at various ports on the west coast had led to a large portion of the 2021 crop remaining in storage until they could be shipped overseas. However, thanks in large part to persistent advocacy campaigns by the Almond Alliance of California, relief to the volume build-up is now underway, as containers and equipment to ship almonds overseas have again been made available. While this relief comes just in time for the upcoming crop to be harvested, a significant volume build-up of the 2021 crop remains. As such, pricing of almonds is expected to remain soft through at least the beginning of summer. ESG Initiatives: Gladstone Land announced the following regarding certain sustainability initiatives it has recently taken or is currently undertaking: The Company currently has solar arrays on 12 of its farms in California, which generate electricity to power the operations on the farms, and windmills on 6 of its farms in Colorado, which power certain wells. The Company is close to finalizing an agreement to add up to 60 wind turbines, 1,600 acres of solar panels, and additional infrastructure as part of a renewable energy agreement on 16,500 acres. The Company is in negotiations to potentially install additional wind turbines and solar panels on certain other farms, as well. The Company owns a 3,586-acre "water farm" in Florida that is part of a state-funded project to divert nutrient-rich tributary water that can cause damaging algae blooms in coastal ecosystems. Many of the Company's farms are enrolled in various conservation programs. Management intends to release a report noting further ESG initiatives in the near future. Lease Renewals and Upcoming Expirations: Since May 10, 2022, the Company has renewed the lease on one of its farms in Colorado, which is expected to result in an increase in annual net operating income of approximately $149,000, or 48.3%. The Company only has one lease expiring over the next six months, which makes up less than 0.5% of its total annual lease revenues. Management currently expects the renewal of this lease to be flat-to-slightly-higher relative to the current lease. Current Debt and Increases in Interest Rates: The Company currently has approximately $665.7 million of total debt outstanding. Over 99.8% of these borrowings are at fixed rates, and on a weighted-average basis, the interest rate on these borrowings is fixed at just 3.25% for the next 5.3 years. As such, management believes its current debt situation is well-protected against continued interest rate increases, as is currently expected. Participation Rents: The Company recorded approximately $5.2 million of additional revenue from participation rents during fiscal year 2021, as compared to approximately $2.4 million in each of 2020 and 2019. Management is currently expecting another strong year of participation rents, as the Company has several additional farms with participation rent components becoming active for the first time during 2022. However, the Company is still awaiting final numbers for crop pricing and yields on most of these farms and looks forward to releasing these results during the second half of the year. Acquisition Outlook: The Company currently has three prospective farmland acquisitions under signed purchase and sale agreements for a total of approximately $85 million that it hopes to complete over the next few months. From 2019 through 2021, the Company acquired over $806 million of new farms, with approximately 79% of these being completed during the last seven months of each fiscal year. Following a similar fashion, management expects acquisition activity to pick up during the second half of the year.

08:51 EDT American Rare Earth changes name to reELEMENT Technologies - American Resources Corporation announced that its majority-owned American Rare Earth division has changed its name to reELEMENT Technologies LLC. The name change aims to better reflect its mandate of producing and supplying high-purity magnet and battery grade rare earth and critical elements to the domestic supply chain while also focusing on the sustainability of these raw materials.

08:48 EDT INNOVATE Corp. announces three directors will not stand for re-election - INNOVATE announced that directors Michael Gorzynski, Shelly Lombard and Kenneth Courtis have informed the Company that they will not stand for re-election to the Board of Directors at INNOVATE's 2022 Annual Meeting of Stockholders. Gorzynski, Lombard and Courtis each irrevocably tendered their resignations as directors of INNOVATE's Board and any of INNOVATE's subsidiaries, including any applicable committee or subcommittee of the Board or any subsidiary, in each case. Their resignations will be effective as of 12:01 a.m., Eastern Time on June 17, 2022. No other nominees for election at the Annual Meeting will be named. The Board of Directors intends to identify new independent directors and expeditiously fill the three Board vacancies.

08:46 EDT Omniq awarded $29M project by Fortune 100 company - OMNIQ announced that it has received a purchase order with a total value of $29M from a fortune 100 company with 70+ billion in annual revenue, hundreds of locations globally with more than 10,000 employees. The purchase order is for a vast upgrade from legacy windows equipment to updated android based technology platform & devices and is to be used to enhance inventory management and reorder processes.

08:44 EDT Jerash Holdings authorizes $3M share repurchase program - Jerash Holdings announced that its board of directors authorized a share repurchase program under which the Company may repurchase up to $3M of its outstanding shares of common stock. The share repurchase program will be in effect through the end of the Company's current fiscal year, March 31, 2023. Under the program, the Company expects to make share repurchases from time to time in the open market, through privately negotiated transactions, by block-purchases or through other transactions managed by broker-dealers, or otherwise, subject to applicable laws, regulations and approvals. The timing of the share repurchases will depend on a variety of factors, including market conditions, and the share repurchase program may be suspended or discontinued at any time.

08:42 EDT Intrado introduces Power Access solution - Intrado Corporation announced the launch of Intrado Power Access, a cloud-enabled solution designed to make operations within Public Safety Answering Points more efficient, flexible, and cost-effective. With the advent of Next Generation 911, PSAPs across the country face challenges as they strive to meet NENA i3 standards for their data and manage requests for assistance from a vast, ever-growing number of sources enabled by 5G communications and the Internet of Things. Intrado is evolving its proven emergency communications solutions to help meet these challenges with new capabilities hosted in the Intrado Life & Safety cloud environment.

08:41 EDT HeartCore Enterprises launches HR digital transformation service - HeartCore Enterprises announced the launch of its latest service offering, the Human Resources, HR, Digital Transformation Development Service, to help implement and advance HR related digital transformation initiatives for its enterprise-level customers. "HeartCore has deep experience in supporting its clients with their digital transformation efforts through our robotics process automation, process mining and task mining software," said CEO Sumitaka Yamamoto. "After several years of operating within the industry, we have identified that a majority of corporations tend to lack an understanding of digital transformation, and that is why our mission is to help clients optimize operational efficiencies by automating certain key businesses functions. I am confident that our team of experts will be able to provide clients with world-class service in kickstarting or refining their digital transformation initiatives."

08:40 EDT ProPhase Labs announces significant laboratory expansion - ProPhase Labs announced that it has partnered with world-renowned healthcare diagnostics innovators for new clinical chemistry, immunoassay, hematology, hemostasis and urinalysis analyzers as part of its plan to significantly expand its in-house clinical testing capabilities. State-of-the-art clinical testing equipment has been procured and a new lease executed for additional space at the company's corporate headquarters in Garden City, New York. Plans are also under way to expand the company's in-house genomics testing offerings. The additional space announced today will be used to expand the company's high complexity molecular diagnostics laboratory services to include traditional clinical testing across multiple specialty areas. Ted Karkus, ProPhase Lab's Chief Executive Officer, commented, "We are very excited to broaden ProPhase's testing capabilities at our Garden City headquarters. In addition to leveraging our established customer base for COVID-19 and upper respiratory testing, with this new space we will be able to offer crucial clinical diagnostics testing that is scalable and can be tailored to the specific needs of physicians and research organizations. In parallel, as we build out our genomics laboratory, we will be able to provide physician tailored genetic tests as well as whole genome sequencing for universities conducting genetic research. Genetic research is a major growth industry, continually working to develop more precise diagnoses and treatments. This research may ultimately prevent major illnesses, making it one of the most important life science fields."

08:39 EDT MamaMancini's appoints Kay to board of directors - MamaMancini's Holdings announced that the Company has appointed M&A industry veteran Mike Kay to the Board of Directors, effective immediately. Concurrently, Patrick Connor Haley has submitted his resignation as Director of the Company to pursue other business obligations. Kay is an Operating Partner at Angeles Equity Partners. He currents serves on the board of two Angeles portfolio companies: Primus Aerospace and Robex.

08:38 EDT Navitas Semiconductor highlights Power IC Technology at 'GaN Marathon' - Navitas Semiconductor has announced its participation in the third 'GaN Marathon' Workshop taking place in Venice, Italy from June 20th - 22nd. GaN is a next-generation power semiconductor technology running 20 times faster than traditional silicon. Compared with traditional silicon chargers, gallium nitride chargers can achieve 3x the power or 3x faster charging with up to 40% energy savings in just half the size and weight of legacy silicon solutions. GaNFast ICs integrate GaN power with drive, control, protection and sensing to enable faster charging, higher power density and greater energy savings for mobile, consumer, enterprise, eMobility and new-energy markets.

08:36 EDT White Gold commences 2022 Diamond Drill Program - White Gold is pleased to announce the commencement of its 2022 diamond drill program at the Ryan's Surprise and Ulli's Ridge targets on its White Gold property. These targets occur in the southern part of a 6.5 km long north-northwest gold-arsenic geochemical trend and are located approximately 2 km west of the Company's flagship Golden Saddle and Arc deposits which have a combined mineral resource of 1,139,900 ounces Indicated at 2.28 g/t Au and 402,100 ounces Inferred at 1.39 g/t Au. The Company's VG deposit, located approximately 11 km to the north, has an Inferred gold resource of 267,600 ounces at 1.62 g/t Au. This diamond drill program forms part of the Company's 2022 fully funded $6 million exploration program on its extensive and underexplored 350,000 hectare land package in the emerging White Gold District, Yukon, supported by strategic partners including Agnico Eagle Mines and Kinross Gold Corporation. Highlights of 2022 Exploration Program on the White Gold Property: Include Approximately 2,700 m of diamond drilling is planned to further test 3 target areas: Area around the newly discovered high-grade gold zone at Ulli's Ridge, with hole WHTULR21D004 returning 6.94 g/t Au over 19.5 m. Gap area between the Ryan's Surprise and Ulli's Ridge target to determine if they form part of the same mineralized zone. Infill drilling at Ryan's Surprise to provide sufficient drill spacing to conduct a potential initial mineral resource estimate. Additional planned 2022 work on the property includes a focused prospecting program along the entire length of the 6.5 km long Ryan's Trend, with rotary air blast drilling of the highest priority targets scheduled in late season. The Company will be exhibiting at PDAC 2022 at booth #3333 in the Investors Exchange from June 13th to 15th from 10 a.m. to 5 p.m. ET. Conference attendees are encouraged to visit to learn more about the Company and ask any questions they may have. Additional details on upcoming diamond drilling on the Betty Property and other components of the 2022 exploration program will be released in the coming weeks. The diamond drilling at Ryan's Surprise and Ulli's Ridge is expected to be carried out in 2 phases, with the initial phase targeting the high-grade gold zone at Ulli's Ridge and the gap area between the Ryan's Surprise and Ulli's Ridge targets. The drill rig will then be moved south to the Company's Betty property to complete the planned diamond drilling program at the Betty Ford and Mascot targets, before returning later in the season to complete the second phase of infill drilling at Ryan's Surprise. Assay results for all drill programs will be released as they become available and interpreted by the Company.

08:33 EDT AIM ImmunoTech announces Netherlands Patent Office issued patent on Ampligen - AIM ImmunoTech announced that the Netherlands Patent Office has issued Patent No. 2027383 - a utility patent - covering Ampligen and other AIM developed dsRNA products for use in the prevention or treatment of COVID-19, with a base patent term extending until 2041. Ampligen is AIM's RNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is designed to modulate the immune system and has demonstrated anti-viral activity. Thomas Equels, M.S. J.D., Chief Executive Officer of AIM, stated, "Over the course of the past few years, we have steadily been working to bolster and expand our patent portfolio covering COVID-19. This new utility patent in the Netherlands is directed to a composition comprising a therapeutic double-stranded RNA product being developed by AIM for use in treating or preventing a SARS-CoV-2 virus infection, including COVID-19 an infectious disease caused by a SARS-CoV-2 virus infection. In one embodiment, the therapeutic double-stranded RNA product may comprise Ampligen. In another patent embodiment, the therapeutic double-stranded RNA product may be one or more of a number of therapeutic double-stranded RNA (tdsRNA) developed by AIM. An example of such tdsRNA includes the rugged double-stranded RNA which is patented via composition of matter patent by AIM in the U.S. and worldwide. Data from in vitro, pre-clinical and clinical experiments strongly suggest that Ampligen has a broad-spectrum early onset anti-viral effect by stimulating a powerful innate immune response not stimulated by the target virus due to the virus' characteristics which stymie the natural immune response inhibiting viral replication. This new utility patent is also directed to a composition comprising a vaccine against SARS-CoV-2 virus and Ampligen designed to, in part, provide expanded immunity against future variants and also provide a similar response enhancing natural immunity post-infection, where Ampligen is administered as an early onset intranasal therapy."

08:32 EDT Avid Bioservices announces further expansion of process development capacity - Avid Bioservices announced that the company is further expanding its process development capacity for its mammalian cell business. As part of these efforts, Avid is expanding its state-of-the-art laboratories which could support an additional $20M in annual process development revenue, doubling the company's current process development capacity. The company estimates that this expansion will cost approximately $6M and completion is anticipated by the end of calendar 2022. This expansion follows previous investments in increased process development capacity made in fiscal year 2019 and the most recent addition of high throughput capabilities in both upstream and downstream processing in fiscal year 2022. "Avid continues to diligently and strategically expand our capacity across all segments of our CDMO business in order to ensure that we are always able to meet the needs of current and future customers. This latest project will generate additional upstream and downstream process development capacity at the front-end of our mammalian cell business, which is critical for the efficient on-boarding of new customer projects," said Nick Green, president and chief executive officer of Avid Bioservices. "With several expansion projects underway across various facilities and business segments, we feel that we are well positioned to take advantage of the increasing demand for high-quality CDMO services and continue to rapidly grow our revenue."

08:30 EDT Intra-Cellular announces presentations at the ISBD on ITI-007 - Intra-Cellular Therapies announced data presentations at the 2022 International Society for Bipolar Disorders, ISBD, Experience held virtually June 10-12, 2022. Three posters were presented on Saturday June 11, 2022 during the "In the Spotlight: Live Posters 2" session. "Lumateperone in the Treatment of Bipolar Depression: Efficacy Across Symptoms;" This poster presents additional analysis from Study 4041. This Phase 3 study established the efficacy and safety of lumateperone 42 mg monotherapy in patients with bipolar I or bipolar II depression. In this study, lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the Montgomery-Asberg Depression Rating total score. "Effect of Lumateperone on Quality of Life and Functional Disability in the Treatment of Bipolar Depression:" This poster expands upon published data which highlights the effects of lumateperone on quality-of-life secondary endpoint in Study 404, a Phase 3 clinical trial evaluating lumateperone as monotherapy for the treatment of patients with Bipolar I or Bipolar II disorder experiencing a major depressive episode. In this Study, lumateperone 42 mg met both primary and key secondary endpoints and these results were published in The American Journal of Psychiatry2. The analysis presented at ISBD investigated lumateperone's improvements in functional disability and quality of life as measured by the prespecified secondary outcome measure, the Quality-of-Life Enjoyment and Satisfaction Questionnaire-Short Form. Results showed lumateperone 42 mg treatment resulted in a mean 10.1-point improvement from baseline in the Q-LES-Q-SF Total score to Day 43 while placebo showed a 7.3-point improvement. "Metabolic Syndrome in Bipolar Depression with Lumateperone : A Post Hoc Analysis of 2 Randomized, Placebo-Controlled Trials:" This poster describes a pooled analysis of Studies 404 and 401 comparing the incidence of and shifts in metabolic syndrome with lumateperone 42 mg as monotherapy and placebo in the treatment of bipolar depression in patients with bipolar I and bipolar II disorder. In this pooled analysis, the rates of MetSy were similar between lumateperone and placebo at baseline and remained stable at end of treatment for both groups. More patients who received lumateperone compared with placebo improved from having MetSy at baseline to no longer meeting MetSy criteria at end of treatment.

08:30 EDT Electro Sensors trading resumes

08:28 EDT Lantheus highlights preliminary study results of PD-L1 expression in cancer - Lantheus Holdings presented preliminary results of the PD-L1 Expression in Cancer, PECan, study at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting. The results suggest that NM-01, a proprietary technetium 99m SPECT/CT imaging agent currently under development to assess PD-L1 expression in cancer cells, has the potential to identify patients who will respond to checkpoint inhibitor therapies and monitor early response in non-small cell lung cancer, NSCLC, pending further and ongoing investigation. In the preliminary analysis, investigators were able to evidence intertumoral heterogeneity of PD-L1 expression between primary tumors and metastases. The PECan study is planned to enroll 15 advanced NSCLC and 15 melanoma patients. The presentation reported the results of the first 10 NSCLC patients. Thoracic NM-01 SPECT/CT imaging was performed at two hours post injection of NM-01 before and after 9-weeks of an immunotherapy, anti-PD-1 pembrolizumab, alone or in combination with chemotherapy. The primary objective with respect to NSCLC is to determine the percentage change in PD-L1 expression between baseline and 9-week NM-01 SPECT/CT in patients receiving treatment. Intertumoral heterogeneity of PD-L1 expression measured on baseline NM-01 SPECT/CT was present in 6 of 10 patients. Response to treatment as assessed by change in 18F-FDG-PET/CT at 9-weeks correlated with high baseline PD-L1 expression measured by NM-01 T:BP, but not with IHC results. Primary tumor baseline NM-01 T:BP greater than or equal to 4.0 predicted 9-week metabolic response with 100% sensitivity and specificity. Metastasis NM-01 T:BP greater than or equal to2.65 predicted metabolic response with 72% sensitivity and 100% specificity. A majority of the primary or metastatic lesions that showed metabolic response were associated with stable or decreased PD-L1 expression by NM-01. The study is ongoing and final results will be presented at a future date.

08:27 EDT Azure Power executes MSA with Premier Energies Group - Azure Power Global announced that it has executed a Module Supply Agreement with Premier Energies Group, one of India's leading manufacturers of solar PV cells and modules, for supply of modules up to 600 MW p.a. for next four years. The company also entered into an agreement to invest ~$12.9M in the Premier Group, of which an investment of ~$5.9M has been made for the subscription of equity shares & compulsorily convertible debentures issued by Premier Energies Investment Private Limited, towards subscription of 26% shareholding in PEIPL. The balance of ~$7M will be made in the form of subscription to optionally convertible debentures issued by Premier Energy Limited. PEIPL is setting up a 1 GW cell and module manufacturing facility in India as part of its expansion plans.

08:25 EDT aTyr Pharma to present findings from tRNA synthetase platform - aTyr Pharma announced that Leslie A. Nangle, Ph.D., Vice President, Research at aTyr, will present at the International 28th tRNA Conference, which is scheduled to take place June 12 - 16, 2022, at The Ohio State University in Columbus, OH. Extracellular tRNA synthetases represent a class of proteins that may play important roles in regulating cellular responses to certain disease states, in particular, cellular stress and imbalances in tissue homeostasis. aTyr is focused on elucidating novel pathways mediated through extracellular tRNA synthetases and creating new biologics to modulate these pathways, by either developing protein therapies based on extracellular tRNA synthetase fragments or generating monoclonal antibodies to target the pathway. Dr. Nangle will participate in a panel with other tRNA focused companies to discuss emerging opportunities in tRNA therapeutics. Additionally, she will present on aTyr's tRNA synthetase platform, including clinical proof-of-concept data from its lead tRNA synthetase derived candidate efzofitimod, which is entering Phase 3 clinical development for the treatment of pulmonary sarcoidosis, a major form of interstitial lung disease.

08:24 EDT Olink selected by FinnGen to provide proteomics data - Olink Holding AB announced that FinnGen in Finland will use Olink technology to provide detailed proteomics data to improve understanding of human health. The FinnGen study has so far identified over 400 new disease-associated loci where the associated gene variant is enriched in the Finnish population. Olink has been chosen by FinnGen to provide comprehensive proteomics profiling of up to 2500 individuals as part of the study. These findings can serve as the basis for further functional studies in combination with high quality proteomics, providing the potential for new insights into disease mechanisms.

08:23 EDT BridgeBio shares data from Phase 2b trial of encaleret - BridgeBio Pharma announced positive Phase 2b data of encaleret in patients with autosomal dominant hypocalcemia type 1, ADH1. The results are featured in an oral presentation at the Endocrine Society, ENDO, 2022 Annual Conference in Atlanta, GA. Thirteen adults with ADH1 caused by nine unique CASR variants participated in the three-period, Phase 2b, open-label, dose-ranging study. Oral calcium and activated vitamin D supplements were discontinued prior to encaleret initiation. Periods 1 and 2 each evaluated encaleret over the course of five inpatient days and Period 3 included a 24-week outpatient evaluation. Key results from the Phase 2b study include: Encaleret was well tolerated with no serious adverse events reported; there were no treatment discontinuations or study withdrawals; Key biochemical parameters of mineral homeostasis, summarized in the table below, were normalized by Period 2, Day 5 and were sustained through Period 3, Week 24 of the trial. BridgeBio plans to initiate the Phase 3 trial in the second half of 2022 with an expected readout of top line data at the end of 2023.

08:22 EDT Binance CEO says Bitcoin withdrawals temporarily paused on platform - Changpeng Zhao, CEO of Binance, tweeted: "Temporary pause of $BTC withdrawals on #Binance due to a stuck transaction causing a backlog. Should be fixed in ~30 minutes. Will update. Funds are SAFU." Reference Link

08:21 EDT Aeterna Zentaris achieves proof-of-concept for treatment of NMOSD - Aeterna Zentaris announced its Autoimmunity Modifying, AIM, Biologicals program has achieved pre-clinical proof-of-concept for the potential treatment of neuromyelitis optica spectrum disorder, NMOSD, a chronic autoimmune disorder of the brain and spinal cord dominated by inflammation of the optic nerve and spinal cord and which can be fatal in approximately 30% of patients within five years of diagnosis. These findings were presented at the 13th International Congress on Autoimmunity being held June 10-13, 2022 in Athens, Greece. The abstract presented at the Congress, titled "Antigen presentation on MHC class Ib-related molecules induces Aquaporin-4-specific regulatory T cells in PBMC and prevents experimental autoimmune encephalomyelitis in mice." "There remains strong unmet medical need to provide treatment options for patients diagnosed with NMOSD, a rare but potentially devastating autoimmune condition. Given the severe impact NMOSD can have on people, we are very encouraged by the proof-of concept our AIM Biologicals program has demonstrated in both in vitro and mouse models," said Dr. Klaus Paulini, Chief Executive Officer of Aeterna. "We are grateful for the collaborative work being done with Dr. Bruttel, Prof. Wischhusen and their team, and we look forward to continue further developing Aeterna's AIM Biologicals for the potential treatment of NMOSD."

08:21 EDT Great Elm Capital announces final results of rights offering - Great Elm Capital announced the final results of its non-transferable rights offering, which entitled holders of rights to purchase one new share of common stock for every one right held at a subscription price of $12.50 per share. The offering expired on June 10, 2022 at 5:00 p.m., New York City time. In total, the Company sold approximately 3.0 million shares of its common stock for aggregate gross proceeds of approximately $37.5 million. The Company intends to use the net proceeds from the offering primarily to to make opportunistic investments, in accordance with its investment objectives and policies, including investments in specialty finance businesses and for general corporate purposes.

08:20 EDT Enphase Energy expands battery storage in Puerto Rico - Enphase Energy announced that installers of Enphase products in Puerto Rico have seen growing deployments of Enphase Energy Systems powered by IQ Microinverters and IQ Batteries, with the grid experiencing frequent outages and climate experts forecasting above-average hurricane activity this year. Homeowners in Puerto Rico can now also choose to install Enphase's IQ8 Microinverters. IQ8 Microinverter-based systems can provide Sunlight Backup functionality during an outage, even without a battery. For homeowners who want battery backup, there are no sizing restrictions on pairing Enphase IQ Batteries with IQ8 Microinverters. Enphase delivers a solar-plus-battery solution that does not expose installers or homeowners to high-voltage direct current. Enphase IQ Batteries feature Lithium Iron Phosphate battery chemistry, which provides a long cycle life and safer operation through excellent thermal stability.

08:19 EDT Global Blood Therapeutics announces results from SHAPE survey - Global Blood Therapeutics announced results from the Sickle Cell Health Awareness, Perspectives and Experiences survey, a multinational survey on the burden of sickle cell disease and unmet needs as reported by more than 1,300 patients, caregivers and healthcare professionals in 10 countries. The findings highlight the significant impact of SCD on everyday life for patients, including fatigue, pain and mental health problems, in addition to impacting their ability to attend and be successful at school or work, and, thereby, reducing their earning potential. One of the largest global burden of disease surveys conducted in SCD, SHAPE identified long-term health complications of SCD as a key concern among patients and HCPs. The survey also revealed that SCD patient caregivers face profound physical, psychosocial, and economic burdens resulting from taking care of people living with the disease. The findings from the HCP portion of the survey were presented during a poster presentation on Friday, June 10, 2022, at the European Hematology Association 2022 Hybrid Congress. SHAPE highlighted the complex environment of treating people living with SCD. The survey results suggest the need for more education and tools to address the long-term impact of the disease and underpin the need for improved overall awareness and understanding of SCD. Key results from this portion of the study include: Despite fatigue/tiredness being identified as having the biggest impact on patients' lives, only half of HCPs felt they have effective tools to treat this symptom. Most HCPs believed that treating hemolytic anemia can improve most aspects of SCD, including reducing organ damage. Most HCPs felt confident in their knowledge of the long-term effects of SCD, but 83% wanted more support in educating their patients on this topic. Nearly one third of HCPs found it challenging to understand patients' concerns, with 43% citing difficulties due to having different ethnic background from their patients. Two-thirds of HCPs felt that patients do not always understand the long-term effects of SCD, and more than one third were reluctant to raise potential future challenges or complications with a patient or their family. Most HCPs agreed that SCD causes financial difficulties for patients, which may consequently affect their access to care. The findings from patients and caregivers highlight that the realities of SCD for both patients and caregivers extend beyond the significant pain often experienced by patients and comprise a broad, lifelong series of physical, emotional and social barriers. Results from the patient and caregiver portions of the survey, which will be featured in an oral presentation on Friday, June 17, 2022, at the 4th Global Congress on Sickle Cell Disease,2 include: Most patients agreed that reducing their risk of long-term health issues due to SCD, such as organ damage, was important to them. Fatigue/tiredness was a symptom experienced by most patients in the past year, which also had the greatest negative impact on their ability to attend and be successful at school or work, and, thereby, on their earning potential. Patients reported that due to SCD they missed an average of 7.5 days of school/work in the past month. Mental health symptoms affected the majority of patients with SCD in the past year, including 62% who reported feeling depressed, low mood or down, and 57% who indicated they felt worry or nervousness. Patients reported more positive experiences with specialist HCPs as compared with emergency departments and general HCPs. More than half of SCD patients reported they believe they had experienced poor care in the past from emergency medicine professionals due to such providers' lack of knowledge about SCD. Over half of caregivers reported that patient symptoms negatively impact their own lives, such as their career and education, long-term health prospects and overall well-being.

08:16 EDT Global Crossing Airlines signs MOU with FreightCloud, Hudson Highland - Global Crossing Airlines Group is pleased to announce the signing of a Memorandum of Understanding with FreightCloud and their financial partner Hudson Highland Partners, for the development of China to the USA e-commerce freight shipment routes, with further redistribution shipments within the Americas. FreightCloud has chartered over 3,000 wide-body freighter flights from China to the US and Europe over the past two years, moving over 150,000 tons of cargo. With GlobalX, FreightCloud intends to develop an Asia-US cargo lane, using GlobalX A321 freighters to move cargo from hubs in Los Angeles, Chicago, and New York, throughout the Americas. Eventually, GlobalX will use its own A330 freighters to move cargo from Asia on behalf of FreightCloud. A321F flights for FreightCloud are expected to commence in Q1 2023, and A330F flights sometime in late 2023, in each case subject to FAA and DOT approvals. The transactions with Freight Cloud and Hudson Highland Partners described in the MOU are subject to certain conditions including the completion of definitive documentation, receipt of regulatory approvals and completion of the FAA freighter certification process and all US DOT approvals.

08:14 EDT Amryt Pharma presents clinical data from OLEs of Mycapssa trials - Amryt presented positive clinical data from the open-label extensions of two of the Phase 3 trials of Mycapssa, OPTIMAL and MPOWERED, at the Endocrine Society's annual meeting, ENDO 2022. Data presented in a late-breaking poster presentation of the 2nd year of the OLE of OPTIMAL , a randomized, double-blind placebo-controlled trial, further support the long-term safety and efficacy of Mycapssa in acromegaly patients who were previously biochemically controlled on monthly injectable somatostatin receptor ligands. Additionally, data presented in a poster presentation of the OLE of MPOWERED, a global, randomized, open-label and active-controlled non-inferiority study, shows improvements in symptom control and patient-reported outcomes in people with acromegaly that received Mycapssa upon entering the OLE from the iSRL arm in the randomized phase Data highlights from the late-breaking poster presentation titled, "Second Year Outcomes of the Open-Label Extension of OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly," include: Maintenance of biochemical response to Mycapssa was durable up to 96 weeks. 100% of subjects who were responders at week 48 and 93% of subjects overall demonstrated a biochemical response at week 96. Median exposure to Mycapssa was 2.1 years, with exposure greater than3 years for 5 patients. Mycapssa's safety profile was consistent with previous studies throughout the OLE; no serious adverse events were reported. Data highlights from the poster presentation titled, "Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open-Label Extension Phase," include: For each of the three full years of the OLE's duration, 90% or more of participating subjects met the OLE's primary endpoint of maintaining a biochemical response to Mycapssa at the end of the year after responding at the start of the year. Patients switching from iSRLs in the RCT phase to Mycapssa during the OLE demonstrated the following: 79% reported very good or excellent symptom control at the end of the OLE, compared with 47% at the end of the RCT phase while receiving iSRLs. Significant improvements in the treatment convenience and treatment satisfaction domains of the Acromegaly Treatment Satisfaction Questionnaire. No new safety signals were observed with long-term Mycapssause compared to the core treatment phase.

08:14 EDT Inhibikase Therapeutics advances IkT-148009 Phase 2 '201' program - Inhibikase Therapeutics announced that it is advancing its Phase 2a study, '201 trial,' following review of the study protocol and Phase 1/1b data by the U.S. FDA.

08:12 EDT Eiger BioPharmaceuticals announces Phase 2b results of avexitide - Eiger BioPharmaceuticals announced Phase 2b results of avexitide in patients with post-bariatric hypoglycemia and hyperinsulinemic hypoglycemia after other gastrointestinal surgeries, demonstrating statistically significant reductions in hypoglycemia and meeting the primary and secondary endpoints of the study. The data were presented by Marilyn Tan, MD, Clinical Associate Professor of Medicine at Stanford University School of Medicine, in an oral presentation on June 11 at the Endocrine Society 2022 meeting in Atlanta, Georgia. This Phase 2b, open-label, investigator-initiated, cross-over study assessed the safety and efficacy of avexitide in hyperinsulinemic hypoglycemia after bariatric or other gastrointestinal surgeries. Sixteen patients with a history of recurrent hypoglycemia refractory to medical nutrition therapy and exhibiting at least two severe hypoglycemia events while adhering to MNT over a 14-day period were included. Metabolic and symptomatic parameters were assessed by self-monitoring of blood glucose, electronic diary and blinded continuous glucose monitoring during 14 days of MNT as compared to 14 days of MNT + avexitide administered by subcutaneous injection at a dose of 45 mg twice daily or 90 mg once daily for a total of 28-days of treatment. The primary and secondary endpoints, which measured frequency of hypoglycemia and amount of time in hypoglycemia, were met with statistical significance. Compared with MNT alone, avexitide 45 mg twice daily and 90 mg once daily reduced the rate of Level 1 hypoglycemia by 54% and 68%, respectively; Level 2 hypoglycemia by 57% and 53%, respectively; and Level 3 hypoglycemia by 68% and 66%, respectively. Objective assessment by blinded CGM, substantiated SMBG, and eDiary results, with both dosing regimens demonstrating significant reductions in hypoglycemia events and time spent in hypoglycemia. A greater magnitude of effect was consistently observed with once daily than twice daily dosing, as measured by blinded CGM. Avexitide was well-tolerated, with no serious adverse events or participant withdrawals. The most common adverse events were diarrhea, headache, and injection site reaction/bruising.

08:10 EDT Bank of America trading team has 'done great' against volatility, says CFO

08:09 EDT Rhythm Pharmaceuticals presents new data from LTE trial on setmelanotide - Rhythm Pharmaceuticals announced new data from the Company's long-term extension, LTE, trial, which show continued body mass index and weight reductions in patients with Bardet-Biedl syndrome or POMC or LEPR deficiency obesity receiving between 18 months and three years of setmelanotide therapy. Rhythm and its collaborators delivered these data in poster presentations at the Endocrine Society Annual Meeting & Expo, being held June 11-14, 2022 in Atlanta. "These presentations build on our strong pivotal trial data and further illustrate setmelanotide's ability to safely deliver sustained, clinically meaningful weight loss for individuals living with severe obesity caused by BBS, or by POMC or LEPR deficiency," said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. "Responses to our precision therapy are shown to be durable, with both adult and pediatric patients experiencing continued reductions in body weight-related measures throughout the long-term extension. This supports our belief in setmelanotide as a chronic therapy across our approved or registration-stage indications. As we approach the June 16 PDUFA goal date for BBS, we are eager to deliver setmelanotide to the waiting community, and we look forward to offering patients and their families a safe, effective medicine that can provide lasting benefit."

08:09 EDT Sirona Biochem announces exclusive licensing agreement with Allergan Aesthetics - Sirona Biochem announced it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona's patents for TFC-1067 and related family of compounds. Under the license agreement, Sirona will a receive an upfront payment and further payments on achievement of milestones and royalties on product sales and has also agreed to financial terms as a supplier of its compounds.

08:08 EDT Bank of America CFO: Credit 'in great shape,' doesn't expect recession

08:08 EDT Mayfair Gold announces further results from Footwall Zone - Mayfair Gold announces further results from the higher-grade Footwall Zone located between 100 and 200 meters to the north of the Fenn-Gib gold deposit. Mayfair's 100% controlled Fenn-Gib Project, located in the Timmins region of Northeast Ontario, hosts the NI 43-101 Indicated Resource of 2.08M ounce Fenn-Gib deposit with disseminated gold mineralization striking east-west on the Pipestone Fault over 1.25 kilometers and up to 300m wide towards the west end. Mayfair Gold President and CEO Patrick Evans noted: "Drilling continues to confirm the higher-grade gold mineralization in the Footwall Zone immediately to the north of the Fenn-Gib deposit. The Footwall Zone mineralization, outcropping at surface and intersected vertically down to approximately 500m below surface, remains open in all directions. The southwest to northeast trending structure has been traced over approx. 200m to date. Drilling is continuing to fully determine the orientation, extent and tonnage potential of the Footwall Zone." Evans added: "The Footwall Zone mineralization is not included in the 2021 NI 43-101 Fenn-Fib resource estimate. Infill and expansion drilling at the main Fenn-Gib deposit is nearing completion and we remain on track to report a resource update in Q3."

08:07 EDT Imperial Oil announces preliminary results of its substantial issuer bid - Imperial Oil announced the preliminary results of its substantial issuer bid , pursuant to which Imperial offered to purchase for cancellation up to $2.5B of its common shares . The Offer proceeded by way of a modified Dutch auction, which had a tender price range from $62.00 per Share to $78.00 per Share, and included the option for shareholders to participate via a proportionate tender. In accordance with the terms and conditions of the Offer and based on the preliminary calculation of Computershare Investor Services Inc., as depositary for the Offer Imperial expects to take up and pay for 32,467,532 Shares at a price of $77.00 per Share under the Offer representing an aggregate purchase of approximately $2.5 billion and 4.9 percent of the total number of Imperial's issued and outstanding Shares as of the close of business on May 2, 2022. Immediately following completion of the Offer, Imperial anticipates that 636,676,182 Shares will be issued and outstanding. 10,260,031 Shares were validly tendered and not withdrawn pursuant to auction tenders at or below the Purchase Price and pursuant to purchase price tenders. Since the Offer was oversubscribed, shareholders who made auction tenders at or below the Purchase Price and shareholders who made, or were deemed to have made, purchase price tenders will have the number of Shares purchased prorated following the determination of the final results of the Offer Imperial currently expects that shareholders who made auction tenders at or below the Purchase Price and shareholders who made, or were deemed to have made, purchase price tenders will have approximately 96 percent of their tendered Shares purchased by Imperial. Shareholders who made auction tenders at a price in excess of the Purchase Price should not expect to have any of their Shares purchased by Imperial. 22,599,766 Shares are anticipated to be taken up and purchased pursuant to proportionate tenders.Exxon Mobil Corporation, Imperial's majority shareholder, made a proportionate tender under the Offer and will maintain its proportionate Share ownership at approximately 69.6 percent following completion of the Offer.

08:06 EDT Bank of America CFO sees mortgage loan growth 'keeping pace'

08:06 EDT Bank of America still seeing good loan growth, says CFO - Comments taken from the Morgan Stanley US Financials, Payments & CRE Conference.

08:05 EDT NightHawk Biosciences appoints Stephan Kutzer as interim CEO of Scorpion - NightHawk Biosciences announced the appointment of Stephan Kutzer, Ph.D. as Interim CEO of Scorpion Biological Services. Dr. Kutzer currently serves on Scorpion's advisory board. He previously served as President and Chief Executive Officer of Alcami Corporation, a leading provider of development, analytical testing and manufacturing services to the pharmaceutical and biotech industries.

08:04 EDT Homology Medicines says FDA lifts clinical hold on pheNIX gene therapy trial - Homology Medicines announced that the U.S. Food and Drug Administration lifted the clinical hold previously placed on the pheNIX gene therapy clinical trial with investigational HMI-102 for adults with phenylketonuria. The FDA noted in its response that Homology satisfactorily addressed all clinical hold issues identified in its letter of March 17, 2022. Homology plans to share the changes to the protocol, which include a new steroid-sparing immunosuppression regimen that incorporates a T-cell inhibitor and a shorter course of steroids, with the clinical trial sites. As previously disclosed, the clinical hold on the pheNIX trial pertained to elevated liver function tests observed in the trial, which were all resolved with no hospitalizations required. Homology's response to the FDA included changes to the protocol intended to enhance risk-mitigation measures and a new immunosuppression regimen with the T-cell inhibitor tacrolimus, which will be used in combination with a reduced duration of prophylactic steroids. The same approach is being used in Homology's ongoing pheEDIT gene editing trial for PKU and juMPStart gene therapy trial for Hunter syndrome. Similar regimens have been shown to dampen the immune response to AAVs in the clinical setting.

08:04 EDT SI-Bone announces FDA clearance for expanded indication of iFuse-TORQ system - SI-BONE announced an FDA clearance for iFuse-TORQ for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures. Fractures covered in this clearance include pelvic fragility fractures and pelvic insufficiency fractures. Together, these constitute an approximately $300M market opportunity. Sacral fragility and insufficiency fractures are common and often devastating for patients and healthcare systems, where: 120,000 sacral fragility or insufficiency fractures occur annually in the US; 78% of patients are treated with bedrest leading to 14- to 45-day hospital stays; 27% 1-year mortality results from bedrest-associated complications. "Since its launch in 2021, iFuse-TORQ has been used to treat many patients suffering from a pelvic fracture or sacroiliac joint dysfunction," said Laura Francis, CEO of SI-BONE. "This pelvic fracture fixation indication expansion comes on the coattails of the iFuse Bedrock Granite launch and expands SI-BONE's position as the market leader in the sacropelvic space."

08:03 EDT Prologis to combine with Duke Realty in $26B all-stock transaction - Prologis (PLD) and Duke Realty ( DRE) "announced that the two companies have entered into a definitive merger agreement by which Prologis will acquire Duke Realty in an all-stock transaction, valued at approximately $26B, including the assumption of debt. The respective board of directors for Prologis and Duke Realty have unanimously approved the transaction. The transaction is anticipated to create immediate accretion of approximately $310-370 million from corporate general and administrative cost savings and operating leverage as well as mark-to-market adjustments on leases and debt. In year one, the transaction is expected to increase annual core funds from operations, excluding promotes per share by $0.20-0.25. On a Core AFFO basis, excluding promotes, the deal is expected to be earnings neutral in year one. Further, future synergies have the potential to generate approximately $375-400 million in annual earnings and value creation, including $70-90 million from incremental property cash flow and Essentials income, $5-10 million in cost of capital savings and $300 million in incremental development value creation. Under the terms of the agreement, Duke Realty shareholders will receive 0.475x of a Prologis share for each Duke Realty share they own. The transaction, which is currently expected to close in the fourth quarter of 2022, is subject to the approval of Prologis and Duke Realty shareholders and other customary closing conditions."

08:02 EDT Ekso Bionics receives FDA clearance to market its EksoNR Robotic Exoskeleton - Ekso Bionics announced it has received 510(k) clearance from the U.S. Food and Drug Administration, FDA, to market its EksoNR robotic exoskeleton for use with Multiple Sclerosis, MS, patients. EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use in patients with MS, an indication which significantly expands the device's use to a broader group of patients. "As a leader in early-to-market wearable robotic solutions for medical rehabilitation, we are committed to maximizing patient access to our technology," said Steven Sherman, Chairman and Chief Executive Officer of Ekso Bionics. "With the indications for use now expanded to include MS, the EksoNR has the potential to assist significantly more patients and improve patient mobility. We are excited to see the device benefit MS patients, providing critically needed rehabilitation solutions just as it has for patients suffering from stroke, spinal cord injury and acquired brain injury." In addition to its FDA clearances, EksoNR is CE-marked and available in Europe. Used by more than 375 rehabilitation centers globally, Ekso devices have helped patients take nearly 200 million steps, while supporting patients' hopes of mobility and independence.

07:55 EDT Electro Sensors trading halted, news pending

07:49 EDT Lantheus presents study results on PYLARIFY AI platform - Lantheus Holdings presented study results providing independent validation of PYLARIFY AI, the Company's artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. PYLARIFY AI is an FDA-cleared medical device software and is commercially available in the United States. The results were presented at the Society of Nuclear Medicine and Molecular Imaging annual meeting and demonstrated the higher efficiency and consistency of the PYLARIFY AI platform while maintaining the diagnostic accuracy of PSMA imaging in prostate cancer. As part of the study, researchers set out to evaluate PYLARIFY AI against manual reads by blinded independent readers who analyzed the 208 patients with biochemical recurrent prostate cancer enrolled in the Phase 3 CONDOR study. A total of 323 lesions were identified by Standard of Truth. In the sensitivity analysis against SOT, one reader demonstrated significant improvement of lesion detection with PYLARIFY AI compared to manual reads. In the other two readers, there was moderate improvement observed compared to manual reads. Median reading times for reader one, two and three were 1.4 minutes, 1.2 minutes, and 1.4 minutes, respectively. The interquartile range of all reading times combined was 2.1 minutes. The reproducibility of per-lesion standard uptake value measurements among the three readers was significantly higher with PYLARIFY AI than without pless than0.0001.

07:46 EDT FDA posts briefing docs for meeting to discuss Moderna vaccine for children - The FDA has posted briefing documents for the Vaccines and Related Biological Products Advisory Committee Meeting being held on June 14-15 to discuss the EUA amendment request for use of the Moderna COVID-19 vaccine in children 6 months through 17 years of age. In the document summary, FDA staff stated: "Myocarditis/pericarditis, in particular in the first week following Dose 2, is a known risk associated with the Moderna COVID-19 Vaccine, with the highest reported rate in males 18-24 years in routine pharmacovigilance/safety surveillance by the CDC and FDA. There were no confirmed cases of myocarditis or pericarditis among participants 6 months through 17 years in clinical studies with mRNA-1273." Reference Link

07:38 EDT Marathon Gold secures $81M equipment financing for Valentine Gold Project - Marathon Gold Corporation announces the execution of a credit-approved commitment letter with Caterpillar Financial Services for equipment lease financing related to the development and operation of the Valentine Gold Project located in central Newfoundland. Matt Manson, President and CEO of Marathon, commented: "We are very happy to be announcing today our equipment leasing commitment with Cat Financial, another significant milestone in our project financing arrangements for the Valentine Gold Project. This agreement will provide financing for the Project's mobile mining equipment through project development and into the first several years of mining operations at an attractive overall cost of capital for Marathon." The commitment letter announced with Cat Financial contemplates $81M of equipment leasing for Caterpillar trucks, excavators, graders, loaders, and dozers, for the purpose of loading, hauling, road maintenance, waste dump maintenance and primary pit support for the Project. The Cat Financial lease will be available to the Company upon release of the Project from its federal Environment Assessment process, review of the Project's updated Feasibility Study, satisfaction of a cost to complete certification, and other customary conditions

07:35 EDT Desktop Metal initiatives seen resulting in $100M in savings over two years - Desktop Metal announced a strategic integration and cost optimization initiative that is projected to result in approximately $40M of annualized run rate non-GAAP cost savings, $20M of which is to take place in the second half of 2022, and at least $100M of aggregate cost savings over the next 24 months. "In 2021, we demonstrated significant growth, expanding our portfolio of products into new markets and innovative materials," said Ric Fulop, Founder and CEO of Desktop Metal. "While the acquisitions we completed in 2021 contributed to this growth and to our total market opportunity as we focused initially on harvesting product and go-to-market synergies, they also increased our cost base and global facilities footprint. Today's announcement of our strategic integration and cost optimization initiative is the result of a comprehensive portfolio and business operations review conducted across all functions at Desktop Metal."

07:35 EDT Cytokinetics announces additional data from REDWOOD-HCM - Cytokinetics announced that additional data from a new analysis of REDWOOD-HCM relating to the effect of treatment with aficamten on measures of cardiac structure and function were presented at the American Society of Echocardiography, ASE, 33rd Annual Scientific Sessions by Theodore Abraham, M.D., F.A.C.C. This new analysis investigated changes from baseline in echocardiographic measures of cardiac structure and function after 10 weeks of treatment with aficamten compared with placebo. At baseline, all patients enrolled in Cohorts 1 and 2 of REDWOOD-HCM had severe left ventricular outflow tract, LVOT, obstruction, 88% had associated systolic anterior motion, SAM, of the mitral valve, and 90% had mitral regurgitation. SAM occurs when the mitral valve leaflet gets pushed against the interventricular septum during systole, resulting in obstruction of the LVOT and mitral regurgitation. Measures of cardiac structure, diastolic and mitral valve function improved at Week 10 in patients treated with aficamten. There was a significant reduction in left atrial volume index and a trend towards a reduction in left ventricular hypertrophy. Treatment with aficamten also resulted in improved ventricular relaxation and filling, as indicated by a reduction in lateral E/e' and an increase in lateral e'. Additionally, treatment with aficamten improved mitral valve dynamics as noted by a reduction in the proportion of patients with SAM and a trend towards a reduction in those with eccentric mitral regurgitation at Week 10. Together, these data point to evidence of early signs of improved cardiac function and structure and improved mitral valve dynamics after a 10-week treatment period with aficamten.

07:34 EDT Selecta Biosciences announces partnership, clinical trial updates - Selecta Biosciences (SELB) announced several pipeline advancements and partnership updates. Sarepta Therapeutics (SRPT) has extended the options under the Research License and Option Agreement to license the rights to develop and commercialize Selecta's immune tolerance platform, ImmTOR, for use in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies. Selecta will receive a $2M payment for the nine-month extension to both options. Additionally, Selecta is eligible to receive an additional $4M payment upon the achievement of certain near-term preclinical milestones by Sarepta. If Sarepta exercises its option to enter a commercial license agreement for DMD or LGMD Selecta will be eligible for additional development, regulatory, and commercial milestone payments, as well as tiered royalties on net product sales. Clinical Pipeline Updates: DISSOLVE II, the second of two Phase 3 clinical studies evaluating SEL-212 for chronic refractory gout, continues to progress. SEL-212 is a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme. Swedish Orphan Biovitrum (BIOVF) has in-licensed SEL-212 from Selecta and is responsible for development, regulatory and commercial activities in all markets outside of China. The Phase 3 program for SEL-212 is being run by Selecta and funded by Sobi. The completion of enrollment in DISSOLVE I & II will result in a $10M milestone payment obligation from Sobi to Selecta. Additionally, Selecta continues to progress its wholly owned gene therapy program, SEL-302 for the treatment of patients with methylmalonic acidemia, toward the clinic. Selecta expects to start a Phase 1 clinical trial in Q4 2022.

07:34 EDT Biohaven Pharmaceutical presents new data on Nurtec ODT, zavegepant - Biohaven Pharmaceutical announced new data from three late-breakers and three oral presentations supporting the safety and efficacy of Nurtec ODT and zavegepant nasal spray for the treatment of migraine. The oral presentations included a first of its kind study in migraine reporting on the safety and benefits of Nurtec ODT when used as a preventive treatment and as-needed for acute treatment of migraine. The data were presented at the 64th Annual Scientific Meeting of the American Headache Society held from June 9-12 in Denver, CO. These new data reinforce Nurtec ODT's efficacy and safety for patients using it to both prevent and treat migraine attacks. Biohaven also presented full Phase 3 efficacy and safety data for zavegepant nasal spray. The data show zavegepant nasal spray was effective for the acute treatment of migraine, achieving its coprimary endpoints and providing an ultra-rapid onset of pain relief at the earliest measured time point of 15 minutes and sustained benefits through 48 hours after a single intranasal dose, with favorable safety and tolerability.

07:33 EDT Enovix announces five-minute charge for Ah Electric Vehicle test cells - Enovix Corporation announced it has demonstrated the ability of its 0.27 Ah Electric Vehicle test cells to charge from 0-80% state-of-charge in as little as 5.2 minutes and achieve a greater than 98% charge capacity in under 10 minutes. On June 14, 2022 Ashok Lahiri, Co-Founder and CTO of Enovix will speak at the 12th International Advanced Automotive Battery Conference Europe in Mainz, Germany. His presentation at 11:20 a.m. titled "Silicon-Anode Lithium-Ion Batteries for EV Applications," will provide an update on the company's EV program. His presentation can be found here. As part of the company's three-year Department of Energy grant program that is pairing a 100% active silicon anode with EV-class cathode materials, the company recently announced its cells surpassed 1,000 cycles while retaining 93% of their capacity. Testing also demonstrated that after six months at elevated temperatures, Enovix batteries had minimal capacity loss. This pairing is projecting a calendar life of greater than 10 years for Enovix batteries.

07:32 EDT Viant names Dustin Kwan as chief product officer - Viant (DSP) announced it has named Dustin Kwan as chief product officer, a newly created executive role intended to drive product strategy at the company. Kwan spent the last 8 years leading ad products at Amazon (AMZN), including growing Amazon DSP to one of the largest demand side platforms in the market.

07:19 EDT Netflix announces 'Squid Game' coming back for season 2 - On Sunday, Netflix announced that the popular show "Squid Game" will officially come back for season 2. Reference Link

07:14 EDT Enthusiast Gaming announces refreshed board of directors - Enthusiast Gaming Holdings announced its director nominees for election to its Board of Directors at the Company's upcoming Annual General Meeting. There are six incumbent director nominees and three new director nominees. Incumbent director nominees include John Albright, Michael Beckerman, Ben Colabrese, Alan Friedman, Adrian Montgomery, and Richard Sherman. Having served as a director of the Company for four years, Francesco Aquilini will not be seeking re-election. Additionally, to fill the open director positions and to further enhance the Board, the Company announces the following new director nominees: Angela Ruggiero, Scott O'Neil, and Seth Berger. Angela Ruggiero: Former Olympian, Capital Markets and Sports and Gaming Board Experience and CEO and co-founder of Sports Innovation Lab, Scott O'Neil: 20 Years of NBA, NHL, and NFL Experience, Venture Capital, and Technology Board Experience and ormer CEO of Harris Blitzer Sports & Entertainment, owner and operator of the Philadelphia 76ers, New Jersey Devils, esports organization Dignitas, and venture capital fund Sixers Innovation Lab. Seth Berger: Gaming and Sports Industry Leader, Innovation and Venture Capital Experience, Key Vendor and Former Significant Shareholder of Outplayed and Managing Director of Sixers Innovation Lab, an early-stage incubation and venture capital fund that invests in early-stage companies in esports & gaming, sports, consumer packaged goods, and media & entertainment, and the birthplace of Outplayed Inc., owner of U.GG.

07:12 EDT Astra Space lower after TROPICS-1 mission did not deliver payloads to orbit - Astra tweeted yesterday regarding its TROPICS-1 mission with NASA: "We had a nominal first stage flight. The upper stage shut down early and we did not deliver the payloads to orbit. We have shared our regrets with @NASA and the payload team. More information will be provided after we complete a full data review." In pre-market trading on Monday morning, Astra shares are down 42c, or 21%, to $1.60. Reference Link

07:10 EDT Apollo Silver announces 2022 Annual General Meeting results - Apollo Silver announced the voting results from its annual general meeting of shareholders held on June 10, 2022. All directors nominated as listed in the information circular dated April 29, 2022, were elected. At the Meeting, the shareholders of the company also approved: the re-appointment of Davison & Company LLP as the auditor of the Company for the ensuing year and authorized the directors to fix their remuneration; and the Company's amended and restated Share Option Plan. The total number of common shares of Apollo represented by shareholders in person or by proxy at the Meeting was 56,233,229 common shares, representing 32.27% of the total issued and outstanding common shares at the record date for the Meeting.

07:10 EDT Lensar announces FDA 510k clearance for next-gen ALLY system - Lensar announced U.S. Food and Drug Administration 510(k) clearance for its next-generation ALLY Adaptive Cataract Treatment System ALLY is the first FDA-cleared platform to enable cataract surgeons to complete the femtosecond-laser-assisted cataract surgery FLACS procedure seamlessly in a single, sterile environment. The Company plans to deliver the first ALLY Systems to surgeons in the third quarter of this year through a controlled and targeted initial launch. Following this launch, the Company plans to make ALLY widely available to cataract surgeons in 2023. "We are elated to bring this proprietary technology to cataract surgeons. Our mission has been to develop a platform where surgeons can seamlessly perform the entire FLACS procedure in a single setting, improve workflow efficiencies, and most importantly, help surgeons deliver better outcomes through the advanced technologies in the ALLY System. We are seeing an overwhelmingly positive response to the ALLY system. Over 125 surgeons have experienced ALLY firsthand, during demonstrations performed at the American Society of Cataract and Refractive Surgery Annual Meeting in April, and more recently at our home office," said Nick Curtis, Chief Executive Officer of LENSAR. ALLY's small footprint and enhanced ergonomics provide surgeons a unique opportunity to improve efficiencies in any operating room or in-office surgical suite. ALLY is the first cataract surgery platform to provide Adaptive Intelligence to automatically determine cataract density, optimize fragmentation patterns, and energy settings, with the goal of minimizing overall energy delivered to complete the cataract procedure more efficiently and help contribute to quicker visual recovery, and better patient outcomes. These proprietary features, combined with advanced astigmatism management technology, have the potential to establish new standards for femtosecond laser cataract surgery procedures. The ability to automate surgeons' treatment plan, while improving time and workflow is a benefit to surgeons, patients, and operating room staff.

07:09 EDT View unveils Smart Building Cloud platform - View announced the industry's first complete, cloud-native platform to enable smart buildings. View will unveil the Smart Building Cloud at Realcomm 2022, the world's largest proptech conference, taking place in Orlando, Florida, June 15-16, where View will be delivering the keynote. The Smart Building Cloud provides real estate technology teams the platform and all software components required to connect, manage, and optimize a portfolio of smart buildings with strong cybersecurity protection and maximum flexibility. The modular, open, secure platform-which extends from network to application-allows IT and digital innovation teams to securely consolidate and normalize building data from across their entire portfolio into a cloud-based environment, and drive business outcomes such as reduced energy consumption and more efficient facilities management with pre-configured insights and automations. Open APIs and out-of-the-box integrations with over forty real estate technology solutions such as SkySpark, Switch Automation, ThingWorx, Rise by VTS, Mapped, and utiliVisor accelerate business value. The Smart Building Cloud can be deployed in both new and existing buildings, and in conjunction with or independently of View Smart Glass, View's flagship product that uses artificial intelligence to optimize access to natural light and outdoor views while keeping occupants comfortable. Every View Smart Glass installation comes with an extensible OT network, View Net, which supports a wide variety of smart building devices and applications and serves as the foundation for a complete smart building technology stack.

07:07 EDT RF Industries receives $6.9M order - RF Industries announced it has received a $6.9M order at the company's Cables Unlimited division for its OptiFlex hybrid fiber solution supporting a new wireless carrier customer. With this order, RF Industries' backlog stands at approximately $34M as of today. The company expects to start shipping against this order towards the end of its current fiscal year 2022. OptiFlex is a composite of multiple cables, including all or a variation of power, coax, ethernet and fiber. This product line is a customizable solution that is engineered and designed to fit the exact needs of RF Industries' customers as they upgrade their wireless tower sites from 3G to 4G and LTE and 5G.

07:06 EDT FDA extends PDUFA goal date for BeiGene for BRUKINSA sNDA to treat CLL, SLL - BeiGene announced that the U.S. Food and Drug Administration FDA has extended the Prescription Drug User Fee Act, PDUFA, goal date by three months to January 20, 2023 for the supplementary new drug application sNDA for BRUKINSA as a treatment for adult patients with chronic lymphocytic leukemia ,CLL, or small lymphocytic lymphoma SLL. The FDA extended the PDUFA goal date to allow time to review additional clinical data submitted by BeiGene, which was deemed a major amendment to the sNDA. The submission included final response analysis from the global ALPINE clinical trial showing BRUKINSA demonstrated superiority versus ibrutinib in overall response rate ORR as assessed by an Independent Review Committee IRC in adult patients with relapsed or refractory R/R CLL or SLL. This final response analysis was announced by the company on April 11. "We will continue to work closely with the FDA to facilitate the review of our sNDA for BRUKINSA in CLL/SLL," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. "We are confident that the data in our filing demonstrate BRUKINSA's potential in the treatment of CLL/SLL and are committed to bringing this important medicine to CLL/SLL patients in the U.S. as soon as possible following regulatory approval."

07:06 EDT Ionis Pharmaceuticals: FDA grants orphan drug designation to ION582 - Ionis Pharmaceuticals announced that the U.S. FDA has granted orphan drug designation and rare pediatric disease designation to ION582, an investigational antisense medicine for the treatment of Angelman syndrome, a rare neurogenetic disorder caused by the loss of function of the maternally inherited Ubiquitin Protein Ligase E3A gene. ION582 targets UBE3A.

07:05 EDT American Outdoor Brands names Arturo Del Rio as Chief People Officer - American Outdoor Brands announced that Arturo Del Rio has joined the company as Vice President of Human Resources & Chief People Officer. In this newly created role, Del Rio will oversee global human resources for the company. He will be responsible for developing and implementing human capital strategies for the organization to include recruiting, training, development, performance management, compensation, and diversity and inclusion initiatives. He most recently served as Global Human Resources Director at Ferro Corporation, a 1.6B global producer of technology-based performance materials for manufacturers

07:03 EDT G1 Therapeutics completes enrollment in Phase 3 trial of trilaciclib - G1 Therapeutics announced that the last patient has been randomized in the Phase 3 clinical trial of trilaciclib for patients with metastatic colorectal cancer receiving chemotherapy. Enrollment is complete at 326 randomized patients; the trial was over-enrolled by approximately 10 percent to compensate for potential loss to follow up at trial sites in Ukraine. Trilaciclib, an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes. It is approved by the U.S. Food and Drug Administration in another indication. "FOLFOXIRI is an important chemotherapeutic backbone for people diagnosed with CRC because it is highly efficacious and has shown a survival advantage compared to other chemotherapeutic options; however, it is also the most myelotoxic regimen, so patients may have dose delays and reductions or receive less effective chemotherapeutic regimens - both of which could impact patient outcome and survival," said Raj Malik, M.D., G1's Chief Medical Officer. "Trilaciclib may be an important addition to this regimen due to its unique ability to preferentially protect the bone marrow from chemotherapy-induced toxicities, and its potential to preserve immune system function and improve survival. Both endpoints are being assessed in PRESERVE 1. We are happy to have completed enrollment, and look forward to presenting initial data, including the primary endpoint of the trial, in the first quarter of 2023. This is a registrational trial; if the data from the primary endpoint are positive, we would work closely with the FDA to expedite our filing for regulatory approval in this indication." PRESERVE 1 is a global multi-center, randomized placebo-controlled, line extension pivotal Phase 3 trial of trilaciclib in 326 patients with metastatic CRC receiving first line trilaciclib or placebo administered prior to FOLFOXIRI and bevacizumab. The regimen is given for two consecutive days of every 14-day cycle. Patients are receiving trilaciclib or placebo administered prior to their chemotherapy for a maximum of 12 cycles of induction followed by maintenance therapy. Treatment is administered until disease progression. The primary endpoint is myeloprotection as measured by duration of severe neutropenia and the occurrence of severe neutropenia during induction. Key secondary endpoints include the effects of trilaciclib on chemotherapy-induced fatigue compared with placebo and the effect of trilaciclib on progression free survival and overall survival compared with placebo.

07:03 EDT Bausch + Lomb announces U.S. launch of Revive custom soft contact lenses - Bausch + Lomb announced the U.S. launch of Revive custom soft contact lenses, a new family of customizable soft contact lenses. Available in spherical, toric, multifocal and multifocal toric options, Revive custom soft lenses are designed to meet the vision needs of more patients, including those with high or unique prescriptions.

07:02 EDT Optinose announces positive results of ReOpen2, Phase 3 trial of XHANCE - Optinose announced the statistically significant benefits of XHANCE in the ReOpen2 trial for both the symptoms co-primary endpoint and the CT scan co-primary endpoint. Significant improvement was demonstrated in patients with chronic sinusitis who did not have nasal polyps treated with both doses of XHANCE nasal spray with the Exhalation Delivery System in the ReOpen2 clinical trial compared to patients receiving a vehicle Exhalation Delivery System. The co-primary endpoints were a patient-reported composite symptom score measured at week 4 and an objective measure of disease in the sinus cavities at week 24. "ReOpen2 is a large, international, controlled trial, studying 222 patients with chronic sinusitis who did not also have nasal polyps. Currently there are no FDA-approved drug treatments for this large patient population," said Ramy Mahmoud, MD, MPH, President of Optinose. He went on to say, "With top-line results showing that patients with chronic sinusitis experienced significant improvement in both symptoms and inflammation inside the sinuses, ReOpen2 confirms and builds on the positive results from ReOpen1 and, importantly, provides evidence supporting the effectiveness of XHANCE in the very large chronic sinusitis population without nasal polyps." The safety profile and tolerability of XHANCE in this trial were generally consistent with its currently labelled safety profile. Adverse events occurring at a rate of more than 3% with XHANCE and more common than the Exhalation Delivery System placebo group in this trial were: epistaxis, COVID-19, headache, and depression. When pre-planned analyses are completed, detailed results from ReOpen2 will be submitted for publication in a peer-reviewed journal and for presentation at future medical meetings.

07:02 EDT Else Nutrition to launch in the Canadian market in July - ELSE NUTRITION announced that it will be formally launching in the Canadian market in July 2022, following two years of solid growth in the United States. Else Nutrition will distribute and sell all 3 of its current category segments within the portfolio: Super Cereals, Toddler Nutrition, and the Kids Protein Shakes - spanning both retail and online channels. Else Nutrition Canada will be led by Mr. Avi Markus, former Vice President of Sales Operations for North America, now promoted to Vice President, Country Manager, Canada. Mr. Markus joined the company in early 2020 and was tasked to develop the core infrastructure for retail sales and business development in the US. Mr. Markus, based in Toronto, Ontario, will have a mandate to develop the Else Nutrition brand within the Canadian market via brick & mortar and various online channels. Else Nutrition will launch three flavors of its Super Cereals for Babies, two flavors of its Plant-Based Shakes for Kids, and a Plant-Based Toddler Formula

06:56 EDT Redbox up another 19% amid increase in StockTwits message volume - Shares of Redbox Entertainment are up another 19.5% at $15.77 in pre-market trading following Friday's gains of 39%. The stock is the highest trending name on StockTwits in terms of message volume over the past 24 hours.

06:52 EDT Volta CFO Francois Chadwick to depart on August 22 - The Board will commence a search for a successor to Volta's current CFO, Francois Chadwick, in the coming weeks. As disclosed on June 10, Chadwick will leave Volta on August 22 to pursue another professional opportunity. In addition, as previously disclosed, the Board has formed a CEO Search Committee and is actively engaged in a process to identify a permanent CEO.

06:50 EDT BWX Medical, TRIUMF execute licensing and services agreement - BWX Technologies announced that subsidiary BWXT Medical Ltd. and TRIUMF, Canada's particle accelerator centre, have executed a licensing and services agreement that strengthens their existing partnership for the production of medical isotopes. This agreement will enable BWXT Medical to manufacture high purity Actinium-225 based products for pharmaceutical companies as it continues to build on its medical isotope production operations on the TRIUMF site. Ac-225 is an alpha-emitting isotope used in targeted alpha therapies that combine Ac-225 with specific tumor-seeking targeting vectors to kill metastatic cancer while leaving healthy cells unaffected. Leveraging existing infrastructure, TRIUMF will irradiate thorium-232 targets for BWXT Medical. From this irradiated thorium, BWXT Medical will process and produce high purity Ac-225, sometimes referred to as non-carrier-added Ac-225, for commercial sale, strengthening BWXT Medical's position as a leading global manufacturer and supplier of critical medical isotopes and radiopharmaceuticals. BWXT Medical intends to partner with pharmaceutical and biotechnology companies who intend to develop targeted alpha therapeutics.

06:48 EDT Volta names Vince Cubbage as Interim CEO - Volta announced that its Board of Directors has made several key leadership appointments and new hires to help drive the company's next phase of growth and operational success. The Board has appointed Vincent Cubbage as Interim CEO and hired Stephen Pilatzke as Chief Accounting Officer. The Board also announced today that Brandt Hastings, currently Chief Revenue Officer and Interim CEO, has been promoted to Chief Commercial Officer to capitalize on Volta's growing revenue momentum and market opportunity. Additionally, Drew Lipsher, currently Chief Strategy Officer, has been promoted to Chief Development Officer. Vince Cubbage brings to Volta over 25 years of experience and accomplishment as a private and public company CEO and as an investment banker. He served as CEO, President and Chairman of the Board of Tortoise Acquisition Corp. II, which completed its initial business combination with Volta in August 2021, at which time he joined the Volta Board.

06:46 EDT Uranium Energy to acquire UEX Corporation - Uranium Energy and UEX Corporation announced they have entered into a definitive arrangement agreement, pursuant to which UEC will acquire all of the issued and outstanding common shares of UEX by way of statutory plan of arrangement under the Canada Business Corporations Act. Under the terms of the agreement, each holder of the common shares of UEX will receive 0.0831 of one UEC share in exchange for each UEX Share. This share exchange ratio implies consideration of approximately C$0.43 per UEX Share and a premium of approximately 50% based on the closing price of UEX's shares on the Toronto Stock Exchange on June 10. At closing, existing UEC and UEX shareholders will own approximately 86.3% and 13.7%, respectively, of UEC based on current outstanding common shares. UEX intends to call a meeting of shareholders to be held in August to seek shareholder approval for the arrangement. Completion of the arrangement will require: approval of at least 66 2/3% of the votes cast by UEX shareholders at the UEX Meeting, and approval of a simple majority of the votes cast by UEX shareholders at the UEX Meeting, excluding votes from certain management shareholders, as required under Multilateral Instrument 61-101. Completion of the arrangement is also subject to the receipt of court and stock exchange approvals, and other customary closing conditions for transactions of this nature, such as Investment Canada approval. The agreement provides for, among other things, non-solicitation covenants, with "fiduciary out" provisions that allow UEX to consider and accept a superior proposal, subject to a "right to match period" in favor of UEC. The agreement also provides for a termination fee of $8.25M to be paid by UEX to UEC if the agreement is terminated in certain specified circumstances. In addition, under the agreement UEC has agreed to provide UEX with C$5M funding by way of a private placement of UEX Shares at a price of C$0.43 per UEX Share. Closing of the private placement is subject to the approval of the TSX. The arrangement has been unanimously approved by the board of directors of UEX. The directors and senior officers of UEX, holding in aggregate approximately 0.5% of the issued and outstanding UEX Shares, have entered into voting support agreements with UEC, pursuant to which they have agreed to vote their shares in favor of the arrangement at the UEX Meeting. TD Securities and Sprott Capital Partners have provided opinions to the UEX board of directors to the effect that, as of the date thereof, and based upon and subject to the assumptions, limitations and qualifications stated in such opinions, the consideration to be received by UEX shareholders pursuant to the arrangement is fair, from a financial point of view, to such shareholders. The transaction is expected to close in the third quarter of 2022.

06:38 EDT Endo enters agreement with TLC to commercialize TLC599 - Endo announced that its subsidiary Endo Ventures, or EVL, has executed an agreement with Taiwan Liposome Company, or TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in Phase 3 development for the treatment of osteoarthritis knee pain. Endo currently expects to launch the differentiated branded product in the United States in 2025. Under the terms of the agreement, TLC will primarily be responsible for the development of the product and EVL will primarily be responsible for obtaining regulatory approval and commercialization of the product in the United States. Upon receipt of regulatory approval, Endo will have exclusive rights to manufacture, market, sell and distribute the product in the United States. TLC will receive an upfront payment of $30M and will be eligible to receive up to an additional $110M based on the achievement of certain development, regulatory, and manufacturing milestones related to the initial indication for the treatment of osteoarthritis knee pain. TLC will be eligible to receive payments based on the achievement of certain commercial milestones and royalties based on the product's net sales in the United States. Additionally, TLC will be eligible to receive certain milestone payments for potential future indications. The upfront payment of $30M will be expensed in the second quarter as acquired in-process research and development. This expense was not reflected in Endo's second quarter 2022 financial guidance provided on May 5 as the transaction was signed after the date of the second quarter earnings release.

06:36 EDT Choice Hotels to acquire Radisson Hotel Group Americas for $675M - Choice Hotels and Radisson Hotel Group announced that Choice Hotels has entered into a definitive agreement to acquire the franchise business, operations and intellectual property of Radisson Hotel Group Americas for approximately $675M. The added 624 hotels with over 68,000 rooms expand Choice Hotels' presence in the upscale and core upper-midscale hospitality segments, particularly in the West Coast and Midwest of the United States. Choice Hotels will acquire the franchise business, operations and intellectual property of Radisson Hotels in the United States, Canada, Latin America and the Caribbean, for approximately $675M, inclusive of the real estate value of three owned assets. The acquisition will be funded with cash on hand and revolver borrowings. Radisson Hotel Group Americas comprises the franchise agreements, operations and intellectual property of Radisson Hotels in the United States, Canada, Latin America and the Caribbean, and includes 10 Radisson Blu hotels, 130 Radisson hotels, 9 Radisson Individuals, 1 Park Plaza hotel, 4 Radisson RED hotels, 453 Country Inn & Suites by Radisson and 17 Park Inn by Radisson hotels, as well as the Radisson Inn & Suites and Radisson Collection brands. Choice Hotels will independently own and control the brands in the Americas and will work with the Radisson Hotel Group to drive the growth, continuity and success of the brands. The transaction is not anticipated to change Choice Hotels' current capital allocation strategy related to dividend payment policy and planned share repurchases. The transaction has been unanimously approved by Choice Hotels' board of directors and is expected to close in the second half of 2022, pending regulatory approvals and customary closing requirements.

06:35 EDT Crypto names down sharply as bitcoin falls below $24,000 - Stocks levered to bitcoin prices are down sharply in pre-market trading as the cryptocurrency extended its decline below the $24,000 mark overnight - the lowest level since December of 2020. Bit Digital (BTBT) is down 11.3% at $1.26, Riot Blockchain (RIOT) is down 13.5% at $4.47, Marathon Digital (MARA) is down 13.8% at $6.50, and Coinbase Global (COIN) is down 12.5% at $51.40.

06:31 EDT ImmunoGen announces research collaboration with Oxford BioTherapeutics - ImmunoGen announced a multi-year collaboration to research novel, first-in-class ADCs with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, utilizing ImmunoGen's proprietary linker-payload technology directed to novel targets identified via OBT's proprietary OGAP discovery platform. The companies will support these research and development efforts through joint funding and by using their respective proprietary technologies. As part of the agreement, OBT will receive an upfront payment from ImmunoGen, reflecting OBT's preclinical programs to be included in the collaboration. After antibodies generated by OBT have been coupled with ImmunoGen's proprietary linker-payload technology, each company will have the opportunity to select one or more development programs to further develop on its own. Each company will be eligible to receive milestone payments based on the achievement of pre-specified development and regulatory milestones, as well as tiered royalties as a percentage of worldwide commercial sales, with respect to each program selected by the other company. Once a company has chosen a given program, it will be solely responsible for all R&D costs associated with that specific program.

06:11 EDT Ferroglobe announces MOU with REC Silicon - Ferroglobe is pleased to announce a Memorandum of Understanding with REC Silicon. Under the MOU Ferroglobe commits to leverage its asset platform in the United States to supply high purity silicon metal to REC Silicon aimed at jointly establishing a low-carbon and fully traceable U.S.-based solar supply chain. Recent investment by the Hanwha Group into REC Silicon, in conjunction with Hanwha Group's subsidiary Qcells, has sparked the impetus to expand REC Silicon's long-standing relationship with Ferroglobe and plan for the immediate development of an end-to-end U.S. solar supply chain from silicon metal, to polysilicon, all the way to fully assembled solar modules. The impact of such a project would span from Washington State, to Georgia, West Virginia, and beyond. Passage of Senator Jon Ossoff's Solar Energy Manufacturing for America Act as part of a broad clean energy incentive package would make such plans immediately possible. Ferroglobe will be a critical partner in ensuring steady supply of fully traceable metallurgical grade silicon metal produced in the U.S. from locally sourced raw materials and utilizing its highly skilled domestic workforce. Ferroglobe is one of the world's largest producers of silicon metal and seeks to leverage its technical and operational expertise across sites in West Virginia, Alabama, and Ohio to support this effort. As a leading producer of high-purity electronics and solar grade polysilicon with assets in Moses Lake, Washington and Butte, Montana, REC Silicon is positioned to help lead the U.S.'s clean energy transition. The recent Hanwha investment will enable a re-start of the currently idle Moses Lake plant in 2023 and make available high volumes of cost competitive, high quality, and low carbon solar grade polysilicon. The MOU commits the companies to work together to increase U.S. production and employment at each of the companies' affected facilities.

06:09 EDT Orla Mining to acquire Gold Standard Ventures for C$242M - Orla Mining (ORLA) and Gold Standard Ventures (GSV) are pleased to announce that they have entered into a definitive agreement whereby Orla will acquire all of the issued and outstanding shares of Gold Standard by way of a court-approved plan of arrangement. Gold Standard's key asset is the 100%-owned South Railroad Project, a feasibility-stage, open pit, heap leach project located on the prolific Carlin trend in Nevada. In February 2022, Gold Standard completed a robust Feasibility Study and permitting activities are currently underway. Gold Standard also owns the Lewis Project, a large, strategically located, prospective land package on the Battle Mountain trend in Nevada. Under the terms of the Transaction, Gold Standard shareholders will receive, in exchange for each Gold Standard common share held, 0.1193 of a common share of Orla and C$0.0001. The Consideration implies a purchase price of C$0.655 per Gold Standard Share, or gross consideration of C$242M, and represents a 35% premium based on the close of Gold Standard's and Orla's share price on the Toronto Stock Exchange on June 10, and a 35% premium based on Gold Standard's 10-day volume weighted average price on the TSX for the period ended June 10. Existing shareholders of Orla and Gold Standard will own approximately 87% and 13% of the pro forma company, respectively, following the close of the Transaction. The Transaction is expected to be completed in August.

06:04 EDT Skillsoft to sell SumTotal business to Cornerstone on Demand for $200M cash - Skillsoft announced it has entered into a definitive agreement to sell its SumTotal business, a provider of learning and human capital management software for highly regulated industries, to Cornerstone OnDemand for approximately $200M in a cash transaction. The transaction is expected to close in the second half of 2022, subject to regulatory approvals and other customary closing conditions. The transaction is expected to be immediately accretive to Skillsoft's bookings and revenue growth at closing, each by approximately one percentage point. In fiscal year 2022, on a reported basis SumTotal generated approximately $123M in bookings and $120M in revenue. Adjusted EBITDA was approximately $37 million excluding corporate allocations and approximately $25M including corporate allocations. The company expects SumTotal to be approximately flat across those metrics in fiscal year 2023, which delivers an enterprise value multiple of approximately 8.0x adjusted EBITDA including corporate allocations. Skillsoft will use a portion of the net proceeds from the transaction to partially repay its senior secured term loan B facility. The company expects pro forma fiscal year 2022 net leverage to be approximately 3.7x.

06:01 EDT Steel Partners, Steel Connect enter definitive merger agreement - Steel Partners Holdings (SPLP) and Steel Connect (STCN) announced that they have signed a definitive merger agreement pursuant to which Steel Partners will acquire the remaining common stock of Steel Connect issued and outstanding immediately prior to the effective time of the merger. The holders of Steel Connect's outstanding shares of common stock will receive $1.35 per share in cash and one contingent value right to receive their pro rata share of net proceeds, to the extent such net proceeds exceed $80M plus certain related costs and expenses, if Steel Connect's ModusLink subsidiary is sold during the two-year period following completion of the merger. Upon closing of the merger, Steel Connect will become a wholly owned subsidiary of Steel Partners. The merger is subject to approval by Steel Connect's stockholders, as well as certain other customary closing conditions. The merger is not subject to a financing condition, and is expected to occur in the second half of 2022. Steel Connect will call a meeting of its stockholders for the purpose of voting on the adoption of the merger agreement in due course. The merger agreement includes a "go-shop" period that expires at 11:59 p.m. Eastern time on July 12, 2022, during which Steel Connect may actively solicit and consider alternative acquisition proposals. There can be no assurances that the "go-shop" process will result in a superior proposal, and Steel Connect does not intend to communicate developments regarding the process unless and until Steel Connect determines that additional disclosure is required or desirable.

05:17 EDT Electric Last Mile Solutions announces Chapter 7 bankruptcy filing - Electric Last Mile Solutions announced the company plans to file for Chapter 7 bankruptcy. In February, following the resignations of Jim Taylor, the company's former CEO, and Jason Luo, the company's founder and former executive chairman, the company appointed board member Shauna McIntyre as interim CEO and president. The ELMS board and the new leadership team under McIntyre launched a review of the company's products and commercialization plans. This process included assessing the company's planned product offerings, production plans, and certification processes, including the feasibility of meeting previously announced targets. Based on the findings of the same board-initiated investigation that led to the resignations of Taylor and Luo, ELMS was forced to withdraw financial guidance and declare the company's past financial statements unreliable. The compound effect of these events, along with a pending SEC investigation initiated this year, made it extremely challenging to secure a new auditor and attract additional funding. Ultimately, the board determined, following a review with the assistance of the company's outside advisors, and upon the recommendation of the company's management, that it is in the best interest of the company and the company's stockholders, stakeholders, creditors, and other interested parties to file for Chapter 7 relief.